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1. RMG - Rapid Mixer Granulator
2. QC - Quality Control
3. DQ - Design Qualification
4. IQ - Installation Qualification
5. OQ - Operational Qualification
6. PQ - Performance Qualification
7. USFDA - United States Food & Drug Administration
8. WHO - World Health Organization
9. MOC - Material Of Construction
10. cGMP - Current Good Manufacturing Practice
11. ICH - International Conference on Harmonisation.
12. SVC - Site Validation Committee
13. QA - Quality Assurance
14. VRA - Validation Risk Assessment
15. URS - User Requirement Specification.
16. VP - Validation Plans.
17. SOP - Standard Operating Procedure
18. MVP - Master Validation Plan.
19. API - Active Pharmaceutical Ingredient
20. CTD - Common Technical Document.
21. MedDRA - Medical Dictionary for Regulatory Activities.
22. ISPE - International Society for Pharmaceutical Engineering.
23. QbD - Quality By Design.
24. ASTM - American Society for Testing and Materials
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25. CAQ - Critical Quality Attributes.
26. CDER - Centre For Drug Evaluation And Control.
27. EU - European Union.
28. EMA - European Medicines Agency.
29. FTIR - Fourier transform Infrared Spectroscopy.
30. HbA1c - Glycated hemoglobin or glycosylated hemoglobin.
31. G.I.T - Gastro Intestinal Tract.
32. HDPE - High-density polyethylene (HDPE) or polyethylene high-density.
33. LOD - Loss On Drying.
34. R.P.M - Rotations Per Minute.
35. USP - United States Pharmacopeia.
36. HPLC - High Performance Liquid Chromatography.
37. M.S.D - Mean Standard Deviation,
38. R.S.D - Relative Standard Deviation.
39. NLT - Not Less Than.
40. NMT - Not More Than.
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INTRODUCTION
Oral solid dosage form 1,2:-
The oral route of drug administration is the most important method of administering drug for
systemic effects. Except in certain cases the parental route is not routinely used for self
administration, e.g. insulin. The topical route of administration has only recently been
employed to deliver drugs to the body for systemic effect. The parental route of
administration is important in treating medical emergencies in which the subject is comatose
or cannot swallow. Nevertheless it is probably that at least 90% of all drugs used to provide
systemic effect are administered by oral route. When a new drug is discovered one of the first
question a pharmaceutical company asks is if the drug can effectively administered for its
intended effect by oral route. Drugs that are administered orally, solid oral dosage forms
represent the preferred class of product. Tablets and capsules represent unit dosage forms in
which usual dose of drug has been accurately placed.
Tablets and capsules represent unit dosage forms in which one usual dose of drug has been
accurately placed. By comparison liquid forms such as syrups, suspensions, emulsions,
solutions and elixirs are usually designated to contain one medication in 5-30 ml, such as
dosage measurements are typically error by a factor ranging from 20-50%, when the drug is
administered by patient.
Tablets 3,4:-
In 1843, the first patent for a hand operated device used to form a tablet was granted. Tablets
are defined as solid dosage forms each containing a single dose of one or more active
ingredients, obtained by compressing uniform volumes of particles. They are intended for the
oral administration, some are swallowed whole, some after being chewed. Some are
dissolved or dispersed in aqueous phase before being administered and some are retained in
the mouth, when the active ingredients are “liberated”.
Tablets are used mainly for systemic drug delivery but also for local drug action. For
systemic use drug must be released form tablet that is dissolved in the fluids of mouth,
stomach and intestine and then absorbed into systemic circulation by which it reaches its site
of action.
The tablet is composed of the Active Pharmaceutical Ingredients (API) together with various
excipients. These are biologically inert ingredients which either enhance the therapeutic
effect or are necessary to construct the tablet. The filler or diluents (e.g. Lactose or sorbitol )
area bulking agents, providing a quantity of materials which can accurately be formed into a
tablet. Binders (e.g. methyl cellulose or gelatine) hold the ingredients together so that they
can form a tablet. Lubricants (e.g. magnesium stearate or polyethylene glycol)are added to
reduce the friction between the tablet and the punches and dies so that the tablet compression
and ejection processes are smooth. Disintegrations (e.g. starch or cellulose) are used to
promote wetting and swelling of the tablet so that it breaks up in the gastrointestinal tract;
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this is necessary to ensure dissolution of the API. Superdisintegrants are sometimes used to
greatly speed up the disintegration of the tablet. Additional ingredients may also be added
such as colouring agents, flavouring agents and coating agents. Formulations are designed
using small quantities in a laboratory machine called a powder compaction simulator. This
can prove the manufacturing process and provide information.
Advantages1 :
 They are unit dosage forms and they offer the greatest capabilities of all oral dosage
forms for the greatest dose precision and the least content variability
 Their cost is lowest of all oral dosage forms.
 They are the lightest and most compact oral dosage forms.
 They are in general the easiest and cheapest to package.
 Product identification is potentially the simplest and cheapest, requiring no additional
processing steps when employing an embossed or monogrammed punch face.
 They may provide the greatest ease of swallowing with the least tendency for “hang-
up” above the stomach especially when coated provided the tablet disintegration is
not excessively rapid.
 They lend themselves to certain special release profile products such as enteric or
delayed release products.
 They are better suited to large scale production than other unit oral forms.
Disadvantages1 :
 Some drugs resist compression into dense compacts, owing to their amorphous nature
or flocculent, low density character.
 Drugs with poor wetting, dissolution properties, intermediate to large dosages,
optimum absorption high in the gastrointestinal tract or any combination of these
features may be difficult to impossible to formulate and manufacture as a tablet that
will still provide adequate full drug bioavailability.
 Bitter tasting drugs, drugs with an objectionable odour or drugs that are sensitive to
oxygen or atmospheric moisture may require encapsulation prior to compression or
the tablets may require coating. In such cases the tablets may offer the offer the best
and lowest coast approach.
Types of Tablets1 :
The main reason behind formulation of different types of tablets are to create a delivery
system that is relatively simple and inexpensive to manufacture, provide the dosage form that
is convenient from patients perspective and utilize an approach that is unlikely to add
complexity during regulatory approval process. To perceive each dosage form, tablets here
are classified by their route of administration and by the type of drug the delivery system
represent within that route.
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Oral Tablets for ingestion:
 Standard compressed tablets
 Multiple compressed tablets
 Compression coated tablets
 Layered tablets
 Inlay tablets
 Modified release tablets
 Delayed action tablets
 Targeted action tablets
 Floating tablets
 Colon targeting tablets
 Chewable tablets
 Dispersible tablets
Tablets used in oral cavity:
 Lozenges and troches
 Sublingual tablets
 Buccal tablets
 Dental cones
 Mouth dissolving tablets
Tablets administered by other routes:
 Vaginal tablets
 Implants
Tablets used to prepare solution:
 Effervescent tablets
 Hypodermic tablets
 Soluble tablets
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METHODS INVOLVED IN FORMULATION OF TABLETS5:
 Direct compression
 Dry granulation
 Wet granulation
Direct Compression:
This method is used when a group of ingredients can be blended and placed in a tablet press
to make a tablet without any of the ingredients having to be changed. This is not very
frequent because many tablets have active pharmaceutical ingredients which will not allow
for the direct compression due to their concentration or the excipients used in formulation are
not conducive to direct compression.
Merits of direct compression:
 Cost Effective
 Stability
 Faster Dissolution
 Less wears and tears of punches
 Simplified Validation
Demerits of direct compression:
 Segregation
 Low dilution potential
 Re-workability
 Lubricant sensitivity
 Variation in functionality
GRANULATION:
Granulation is the process of collecting the particles together by creating bonds between
them. There are several different methods of granulation. The most popular being the wet
granulation which is used by over 70% in the formulation of tablets.
Dry Granulation:
In dry granulation process the powder mixture is compressed without the use of heat and
solvent. It is the least desirable of all the methods of granulation. The two basic procedures
are to form a compact of materials by compression and then to mill the compact to obtain
granules. Two methods are used for dry granulation. The more widely used method is
slugging, where the powder is recompressed and the resulting tablet or slug are milled to
yield the granules. The other method is to pre compress the powder with pressure rolls using
a machine as a Chilsonator.
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Roller Compaction:
The compaction of powder by means of pressure roll can also be accomplished by a machine
called Chilsonator. Unlike tablet machine, the chilsonator turns out a compacted mass in a
steady continuous flow. The powder is fed down between the rollers from the hopper which
contains a spiral sugar to feed the powder into the compaction zones. Like slugs the
aggregates are screened or milled for production into granules.
Use: use in the production of directly compressible ecipients, the compaction of drugs and
drug formulations, the granulation of inorganic materials, the granulation of dry herbal
materials and the production of immediate/sustained release formulations.
Processing Steps:
Weighing of raw materials, screening, mixing and compression to slugs-milling-mixing-
compression to finished tablets.
Advantages:
The main advantage of dry granulation or slugging is that it uses less equipment and space.
It eliminates the need for binder solution, heavy mixing equipment and the costly and time
consuming drying step required for wet granulation. Slugging can be used for advantages in
the following situations
I. For moisture sensitive materials
II. For heat sensitive materials
III. For improved disintegration since powder particles are not bonded together by a
binder.
Disadvantages:
I. It requires a specialized heavy duty tablet press to form slug
II. It does not permit uniform colour distribution which can be achieved by wet
granulation where the de can be incorporated into binder liquid.
III. The process tends to create more dust than wet granulation, increasing the potential
for contamination.
Wet Granulation:
The most broadly used process of agglomeration in pharmaceutical industry is wet
granulation. Wet granulation process simply involves the wet massing of the powder blend
with a granulating liquid, wet sizing and drying. Important step involved in the wet
granulations are
i. Mixing of the drug(s) and excipients.
ii. Preparation of binder solution
iii. Mixing of blend solution with powder mixture to form wet mass
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iv. Drying of moist granules
v. Mixing of screened granules with disintegrant, glidant, and lubricant.
Merits:
a) Permits mechanical handling of powders without loss of mix quality.
b) Improves the flow of powders by increasing particle size.
c) Increases and improves the uniformity of powder density.
d) Improves cohesion during and after compaction.
e) Reduces air entrapment.
f) Reduces the level of dust and cross-contamination.
g) Allows for the addition of a liquid phase to powders (wet process only).
h) Makes hydrophobic surfaces hydrophilic.
Demerits:
a) The major limitation of wet granulation is its cost. It’s expensive process because of
labour, time, equipment, energy, space requirements
b) Loss of materials during various stages of processing
c) Stability may be major concern for moisture sensitive or thermolabile drugs.
d) Multiple processing steps add complexity and make validation and control difficult
e) An inherent limitation of wet granulation is that any compatibility between
formulation components is aggravated.
TABLET COATING6:
The application of coating to tablets, which is an additional step in the manufacturing
process, increases the coast of the product; therefore, the decision to coat a tablet is usually
based on the following objectives:
1. To mask the taste, odour, or colour of the drug.
2. To provide physical and chemical protection for the drug.
3. To control the release of the drug from the tablet.
4. To protect the drug from the gastric environment of the stomach with an acid-resistant
enteric coating.
5. To incorporate another drug adjuvant in the coating to avoid chemical
incompatibilities or to provide sequential drug release.
6. To improve the pharmaceutical elegance by use of special colours.
There are two types of coatings they are
I. Sugar coating.
II. Film coating.
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Introduction to Film Coating Materials
A film coating is a thin polymer-based coat applied to a solid dosage form such as a
tablet. The thickness of such a coating is usually between 20-100 µm. Under close
inspection the film structure can be seen to be relatively non- homogenous and quite
distinct in appearance, from a film forming, from casting a polymer solution on a flat
surface.
Film coating formulations usually contain the following components
Polymer,
Plasticizer,
Colourants / Opacifiers,
Solvent/Vehicle.
Polymers
Amongst the vast majority of the polymers used in film coating are cellulose derivatives or
acrylic polymers and copolymers.
Non-enteric polymers
·Hypromellose
·Hydroxyethyl cellulose
·Hydroxyethylmethyl cellulose
·Carboxymethylcellulose sodium
·Hydroxypropyl cellulose
·Polyethylene glycol
·Ethylcellulose
Enteric polymers
Some examples of enteric coating polymers
·Hypromellose phthalate
·Polyvinyl acetate phthalate
·Cellulose acetate phthalate
·Polymethacrylates
·Shellac
Plasticizers
Plasticizers are simply relatively low molecular weight materials which have the capacity to
alter the physical properties of the polymer to render it more useful in performing its function
as a film-coating material. It is generally considered to be mechanism of plasticizer
molecules to interpose themselves between individual polymer strands thus breaking
down polymer-polymer interactions. Thus polymer is converted in to more pliable materials.
Plastisizers are classify in three groups. Polyos type contain glycerol, propylene glycol, PEG(
Polyethylene glycol ). Organic esters contain phthalate esters, dibutyl sebacete, citrate esters,
triacetin. Oils/glycerides contain castor oil, acetylated, monoglycerides and fractionated
coconut oil.
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Solvents/Vehicles
The key function of a solvent system is to dissolve or disperse the polymers and other
additives. All major manufactures of polymers for coating give basic physicochemical
data on their polymers. These data are usually helpful to a formulator. Some important
considerations for solvent are as follows,
The major classes of solvents being used are
·Water
·Alcohols
·Ketones
·Esters
·Chlorinated hydrocarbons
Because of environmental and economic considerations, water is the solvent of choice;
however organic coating is totally cannot be avoided.
Colourants / opacquants
These materials are generally used as ingredients in film-coating formulae to contribute to the
visual appeal of the product, but they also improve the product in other ways
Identification of the product by the manufacturer and therefore act as an aid for existing GMP
procedures.
- Reinforcement of brand imaging and reduction in product counterfeiting.
- Identification of the product by patients by using colourants.
Colourants for film coating are having, in more or less amount, property of opacifier.
So they would give protection to active ingredients in presence of light. Colourants are
mainly classified in to three part. Sunset yellow, tartrazine, erythrosine are examples of
Organic dyes and their lakes. Iron oxide yellow, red and black, titanium dioxide, talc are the
examples of Inorganic colours. Anthrocyanins, ribofloavine and carmine are the examples of
natural colours.
Miscellaneous coating solution components
To provide a dosage form with a single characteristic, special materials may be
incorporated into a solution.
Flavours and sweeteners are added to mask unpleasant odours or to develop the desired
taste. For example, aspartame, various fruit spirits (organic solvent), water soluble pineapple
flavour (aqueous solvent) etc.
Surfactants are supplementary to solubilize immiscible or insoluble ingredients in the
coating. For example, Spans,Tweens etc.
Antioxidants are incorporated to stabilize a dye system to oxidation and colour change. For
example oximes, phenols etc.
Antimicrobials are added to put off microbial growth in the coating composition. Some
aqueous cellulosic coating solutions are mainly prone to microbial growth, and long-
lasting storage of the coating composition should be avoided. For example
alkylisothiazloinone, carbamates, benzothiazoles etc.
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Coating Process
Film-coating of tablets is a multivariate process, with many different factors, such as coating
equipment, coating liquid, and process parameters which affect the pharmaceutical quality of
the final product.
Coating equipment
Before few years different types of coating pans are used for coating like conventional
coating pans, manesty accelacota, driam ( driacoater ), butterfly coater etc. Now a days the
side-vented, perforated pan-coater is the most commonly used coating device of tablets. In
equipment spray nozzle, number of spray nozzle, pan size, etc may also affect the quality of
final product. Its air flow system through a perforated pan ensures rapid and continuous
drying conditions. The low evaporation capacity of water requires high drying efficiency of
aqueous film-coating equipment.
Coating liquid
Coating liquid may affect the final quality of the tablets. Different film former have different
chemical nature and different charesteristic. Viscosity may affect the spreading of coating
liquid across surface of substrate. Surface tension may affect in wetting of surface. % Solid
content generally affect the tablet surface and coating efficiency.
Process parameters
Spray rate
The spray rate is an significant parameter since it impacts the moisture content of the formed
coating and, subsequently, the quality and uniformity of the film.A low coating liquid spray
rate causes incomplete coalescence of polymer due to insufficient wetting, which could effect
in brittle films. A high coating liquid spray rate may result in over wetting of the tablet
surface and subsequent problems such as picking and sticking. If the spray rate is high and
the tablet surface temperature is low, films are not formed during the spraying but the post
drying phase, and rapid drying often produces cracks in the films.
Atomizing air pressure
In general, increasing the spraying air pressure decreases the surface roughness of coated
tablets and produces denser and thinner films. If spraying air pressure is excessive, the spray
loss is great, the formed droplets are very fine and could spray-dry before reaching the tablet
bed, resulting in inadequate droplet spreading and coalescence. If spraying air pressure is
inadequate, the film thickness and thickness variation are greater possibly due to change in
the film density and smaller spray loss. In addition, with low spraying air pressure big
droplets could locally over wet the tablet surface and cause tablets to stick to each other.
Inlet air temperature
The inlet air temperature affects the drying efficiency (i.e. water evaporation) of the coating
pan and the uniformity of coatings. High inlet air temperature increases the drying efficiency
of the aqueous film coating process and a decrease in the water penetration into the tablet
core decreases the core tablet porosity, tensile strength and residual moisture content of
coated tablets. Too much air temperature increases the premature drying of the spray during
application and, subsequently, decreases the coating efficiency. Measuring the pan air
temperature helps to manage the optimum conditions during the coating process and,
consequently, enables predicting possible drying or over wetting problems which may result
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in poor appearance of the film or may have unfavourable effects on the moisture and heat
sensitive tablet cores.
Rotating speed of pan
It is well documented that increasing the rotating speed of the pan improves the mixing of
tablets. The pan speed affects the time the tablets spend on the spraying zone and,
subsequently, the homogeneous distribution of the coating solution on the surface of each
tablet throughout the batch. Increasing the pan speed decreases the thickness variation and
increase the uniformity of coatings. Too much rotating speed of the pan will cause the tablet
to undergo unnecessary attrition and breakage.
Film coating technology is now a day’s very important in the field of pharmacy particularly
in formulation development. Process parameters and coating composition play an important
in coating of tablets. So for getting good final quality of coated tablet it would be necessary
to optimize the parameters.
VALIDATION: Validation is the documented act of demonstrating a procedure, process,
and activity that will consistently lead to the expected results. It is a requirement for good
manufacturing practices and other regulatory requirements. To ensure product quality,
numerous features are required like chemical and physical stability, suitable preservation
against microbial contamination (if appropriate), uniformity of dose of drug, acceptability to
users including prescriber and patient, as well as suitable packing, labelling and validation7.
To further enhance the effectiveness and safety of the drug product after approval many
regulatory agencies such as the United States Food and Drug Administration (USFDA) also
requires that the drug product be tested for its identity, strength, quality, purity and stability
before it can be released for use. For this reason, pharmaceutical validation and process
controls are important in spite of the problems that may be encountered8. Since a wide variety
of procedures, processes, and activities need to be validated, the field of validation is divided
into a number of subsections including the following:
 Cleaning validation
 Process validation
 Analytical method validation
 Computer system validation
Qualifying systems and equipment is divided into a number of subsections including the
following:
 Design qualification (DQ)
 Component qualification (CQ)
 Installation qualification (IQ)
 Operational qualification (OQ)
 Performance qualification (PQ)
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HISTORY9,10: The first validation activities were focused on the process involved in making
these products but quickly spread to associated processes involving environmental control,
media fill, equipment, and sanitization and purified water production. The concept of
validation was first developed for equipment and processes and derived from the engineering
practices used in delivery of large pieces of equipment that would be manufactured, tested,
delivered and accepted according to a contract. The use of validation spread to other areas of
industry after several large-scale problems highlighted the potential risks in the design of
products.
REASONS FOR VALIDATION: Validation is "Establishing documented evidence that
provides a high degree of assurance that a specific process will consistently produce a
product meeting its pre-determined specifications and quality attributes." (FDA1987). A
properly designed system will provide a high degree of assurance that every step, process and
change has been properly evaluated before its implementation. Testing a sample of a final
product is not considered sufficient evidence that every product within a batch meets the
required specification.
NEED FOR VALIDATION 11,12,13:
 It would be feasible to use the equipments without knowing whether it will produce
the product we wanted or not.
 The pharmaceutical industry uses expensive materials, sophisticated facilities &
equipments and highly qualified personnel.
 The efficient use of these resources is necessary for the continued success of the
industry. The cost of product failures rejects reworks and recalls complaints are the
significant parts of the total production cost.
 Detailed study and control of the manufacturing process validation is necessary if
failure to be reduced and productivity improved.
 The Pharmaceutical industries are concerned about validation because of the
following reasons:
a) Assurance of quality
b) Cost reduction
c) Government regulation.
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DEPARTMENTS RESPONSIBLE14:
 SITE VALIDATION COMMITTEE (SVC): Develop site master validation plan,
prepare or execute or approve validation studies.
 PRODUCTION DEPARTMENT: Prepares the batches as a routine production batch.
 QUALITY ASSURANCE: Ensure compliance, see that documentations, procedures
are in place, approves protocols and reports.
 QUALITY CONTROL: Performs testing and reviews protocol and report as needed.
RESPONSIBLE AUTHORITIES FOR VALIDATION:
The working party would usually include the following staff members, preferably those with
a good insight into the company’s operations.
 Head of Quality Assurance
 Head of engineering.
 Validation manager
 Production manager
 Specialist validation discipline: all areas.
Table No 1: Authorities for Validation
DEPARTMENT/DESIGNATION RESPONSIBILITY.
Manager production Responsible for the manufacturing of
batches and reviews of protocol and
reports.
Manager QC Responsible for analysis of sample
collected.
Manager Maintenance Providing utilities and engineering
support.
Executive production Responsible for preparation protocol and
manufacturing of validation batches.
Manager QA Responsible for protocol authorization and
preparation of summary report.
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ESSENTIALS OF PHAMACEUTICAL VALIDATION15,16,17:
Validation is the integral part of the quality assurance; it involves the systematic study of
systems, facilities and processes aimed at determining whether they perform their intended
functions adequately and consistently as specified. A validated process is one which has been
demonstrated to provide a high degree of assurance that uniform batches will be produced
that meet the required specifications and has therefore been formally approved. Validation in
itself does not improve processes but confirms that the processes have been properly
developed and are under control. Adequate validation is beneficial to the manufacturer in
many ways:
1. It deepens the understanding of processes; decreases the risk of preventing problems
and thus assures.
2. The smooth running of the process.
3. It decreases the risk of defect costs.
4. It decreases the risk of regulatory noncompliance.
5. A fully validated process may require less in- process controls and end product
testing.
VALIDATION MASTER PLAN18:
Validation master plan is a document that describes how and when the validation program
will be executed in a facility. Even though it is not mandatory, it is the document that outlines
the principles involved in the qualification of a facility, defines the areas and systems to be
validated and provides a written program for achieving and maintaining a qualified facility
with validated processes. It is the foundation for the validation program and should include
process validation, facility and utility qualification and validation, equipment qualification,
cleaning and computer validation. The validation scope, boundaries and responsibilities for
each process or groups of similar processes or similar equipment's must be documented and
approved in a validation plan. These documents, terms and references for the protocol authors
are for use in setting the scope of their protocols. It must be based on a Validation Risk
Assessment (VRA) to ensure that the scope of validation being authorised is appropriate for
the complexity and importance of the equipment or process under validation. Within the
references given in the VP the protocol authors must ensure that all aspects of the process or
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equipment under qualification; that may affect the efficacy, quality and or records of the
product are properly qualified. Qualification includes the following steps:
 DESIGN QUALIFICATION (DQ) - Demonstrates that the proposed design (or the
existing design for an off-the-shelf item) will satisfy all the requirements that are
defined and detailed in the User Requirements Specification (URS). Satisfactory
execution of the DQ is a mandatory requirement before construction (or procurement)
of the new design can be authorised.
 INSTALLATION QUALIFICATION (IQ) – Demonstrates that the process or
equipment meets all specifications, is installed correctly, and all required components
and documentation needed for continued operation are installed and in place.
 OPERATIONAL QUALIFICATION (OQ) – Demonstrates that all facets of the
process or equipment are operating correctly.
 PERFORMANCE QUALIFICATION (PQ) – Demonstrates that the process or
equipment performs as intended in a consistent manner over time.
 COMPONENT QUALIFICATION (CQ) – is a relatively new term developed in
2005. This term refers to the manufacturing of auxiliary components to ensure that they
are manufactured to the correct design criteria. This could include packaging
components such as folding cartons, shipping cases, labels or even phase change
material. All of these components must have some type of random inspection to ensure
that the third party manufacturer's process is consistently producing components that
are used in the world of GMP at drug or biologic manufacturer.
There are instances when it is more expedient and efficient to transfer some tests or
inspections from the IQ to the OQ or from the OQ to the PQ. This is allowed for in the
regulations, provided that a clear and approved justification is documented in the Validation
Plan (VP)
PHASES OF VALIDATION:
PHASE 1:This is the pre –validation qualification phase which covers all activities relating
to product research and development , formulation pilot batch studies, scale up studies,
transfer of technology to commercial scale batches, establishing stability conditions and
storage  and handling of in process and finished dosage forms, equipment qualification
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installation qualification , master production document, operational qualification and process
capacity.
PHASE 2: This is the process validation phase .It is designed to verify that all established
limits of the critical process parameters are valid and that satisfactory products can be
produced even under the worst conditions.
PHASE 3:This is known as the maintenance phase .It requires frequent review of all process
related documents, including validation of audit reports, to assure that there have been no
changes , deviations , failures and modifications to the production process and that all
standard operating procedures , have been followed, including the change control procedures.
At this stage, the validation team comprising of individual representing all major departments
also assures that there is no changes /deviations that should have resulted in requalification
and revalidation. A careful design and validation of systems and process controls can
establish a high degree of confidence that all lots or batches produced will meet their
intended specifications. It is assumed that throughout manufacturing and control, operations
are conducted in accordance with the principle of good manufacturing practice (GMP). Both
in general and in specific references to sterile product manufacture. The validation steps
recommended in GMP guidelines can be summarized as follows:
1. As a pre-requisite, all studies should be conducted in accordance with a detailed pre-
established protocol or series of protocols, which in turn is subjected to formal-
change control procedures.
2. Both the personnel conducting the studies and those running the process being studied
should be appropriately trained and qualified and be suitable and competent to
perform the task assigned to them.
3. All data generated during the course of studies should be formally reviewed and
certified as evaluated against pre-determined criteria.
4. Suitable testing facilities, equipment instruments and methodology should be
available.
5. Suitable clean room facilities should be available in both the local and background
environment. There should be assurance that the clean room environment as specified
as secured through initial commissioning (qualification) and subsequently through the
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implemented of a program of re- testing –in process equipment should be properly
installed, qualified and maintained.
6. When appropriate attention has been paid to the above, the process, if aseptic, may be
validated by means of process stimulation studies.
7. The process should be revalidated at intervals
8. Comprehensive documentation should be available to define support and record the
overall validation process.
PROCESS SHOULD SPECIFY THE FOLLOWING IN DETAILS:
1. The objective and scope of study – there should already be a definition of purpose.
2. A clear and precise definition of process equipment system or subsystem, which is to
be the subject of study with details of performance characteristics.
3. Installation and qualification requirement for new equipment.
4. Any upgrading requirement for existing equipment with justification for change and
statement of qualification requirements.
5. Detailed stepwise statement of actions to be taken in performing the study.
6. Assignment of responsibility for performing the study.
7. Statement on all the tests methodology to be employed with a precise statement of the
test equipment and/or materials to be used.
8. Test equipment calibration requirements.
9. Requirements for the current format of the reports on the study.
10. References to any relevant standard operating procedures (SOP).
11. Acceptance criteria against which the success (or otherwise) of the study is to be
evaluated.
12. The personnel responsible for evaluating and certifying the acceptability of each stage
in the study and for the final evaluation and certification of the process as a whole as
measured against the pre-defined criteria.
13. All personnel involved in conducting the studies should be properly trained and
qualified because they can, and often, have a crucial effect on the quality of the end
product. All the information or data generated as a result of the study protocol should
be evaluated by qualified individuals against protocol criteria and judged as meeting
or failing the requirements written evidences supporting the evaluation and
conclusion should be considered as having failed to demonstrate acceptability and
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documented. Any failure to follow the procedure as laid down in the protocol must be
considered as potentially compromising the validity of the study itself and requires
critical evaluation of all the impact on the study. The final certification of the
validation study should specify the pre-determined acceptance criteria against which
success or failure was evaluated.
COMPUTER SYSTEM VALIDATION19:
Validation (FDA 2002) defines verification as "Software verification provides objective
evidence that the design outputs of a particular phase of the software development life cycle
meet all of the specified requirements for that phase." It also defines Validation as
"Confirmation by examination and provision of objective evidence that software
specifications conform to user needs and intended uses, and that the particular requirements
implemented through software can be consistently fulfilled.
Weichel (2004) recently found that over twenty warning letters issued by the FDA to
pharmaceutical companies specifically cited problems in Computer System Validation
between 1997 and 2001.
SCOPE OF COMPUTER VALIDATION:
The main implications in this are that validation should cover all aspects of the process
including the application, any hardware that the application uses, any interfaces to other
systems, the users, training and documentation as well as the management of the system and
the validation itself after the system is put into use. The PIC/S guideline (PIC/S 2004) defines
this as a 'computer related system'. Much effort is expended within the industry upon
validation activities, and several journals are dedicated to both the process and methodology
around validation, and the science behind it.
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A SIMPLIFIED DRUG/VALIDATION PATH
Figure no: 1 Simplified validation path
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PROCESS VALIDATION:
INTRODUCTION20,21: This guidance outlines the general principles and approaches that
FDA considers appropriate elements of process validation for the manufacture of human and
animal drug and biological products, including active pharmaceutical ingredients (APIs or
drug substances), collectively referred to in this guidance as drugs or products. This guidance
incorporates principles and approaches that all manufacturers can use to validate
manufacturing processes.  This guidance aligns process validation activities with a product
lifecycle concept and with existing FDA guidance, including the FDA/International
Conference on Harmonization (ICH) guidance for industry, Q8(R2) Pharmaceutical
Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System.2
Although this guidance does not repeat the concepts and principles explained in those
guidance, FDA encourages the use of modern pharmaceutical development concepts, quality
risk management, and quality systems at all stages of the manufacturing process lifecycle20.
the lifecycle concept links product and process development, qualification of the commercial
manufacturing process.
BACKGROUND: In the Federal Register of May 11, 1987, FDA issued a notice announcing
the availability of a guidance entitled Guideline on General Principles of Process Validation
(the 1987 guidance). Since then, we have obtained additional experience through our
regulatory oversight that allows us to update our recommendations to industry on this topic.
This revised guidance conveys FDA’s current thinking on process validation and is consistent
with basic principles first introduced in the 1987 guidance. The revised guidance also
provides recommendations that reflect some of the goals of FDA’s initiative entitled
“Pharmaceutical CGMPs for the 21st Century. A Risk-Based Approach,” particularly with
regard to the use of technological advances in pharmaceutical manufacturing, as well as
implementation of modern risk management and quality system tools and concepts23. This
revised guidance replaces the 1987 guidance. FDA has the authority and responsibility to
inspect and evaluate process validation performed by manufacturers. The cGMP regulations
for validating pharmaceutical (drug) manufacturing require that drug products be produced
with a high degree of assurance of meeting all the attributes they are intended to possess.
DEFINITION: Process validation is the collection and evaluation of data, from the process
design stage throughout production, which establish scientific evidence that a process is
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capable of consistently delivering quality products. Process validation involves a series of the
activities taking place over the lifecycle of the product and process.
United States Food & Drug Administration: Process validation is establishing documented
evidence which provide a high degree of assurance that a specific process consistently
produces a product meeting its predetermined specification and quality attribute.
TYPES OF PROCESS VALIDATION:
Prospective process validation- where an experimental plan called the validation protocol is
executed (following the completion of the qualification trials) before the process is put to
commercial use. Most validation efforts require some degree of prospective experimentation
in order to generate validation support data.
Concurrent Process validation- establishing documented evidence that the process is in a
state of control during the actual implementation of the process .this is normally performed
by the in-process testing and/ or monitoring of critical operations during the manufacture of
each production batch.
Retrospective process validation-where historic data taken from the records of the
completed production batches are used to provide documented evidence that the process has
been in a state of control prior to the request for such evidence.
GENERAL CONSIDERATIONS FOR PROCESS VALIDATION:
In all stages of the product lifecycle, good project management and good archiving that
capture scientific knowledge will make the process validation program more effective and
efficient. The following practices should ensure uniform collection and assessment of
information about the process and enhance the accessibility of such information later in the
product lifecycle.
 Throughout the product lifecycle, various studies can be initiated to discover, observe,
correlate, or confirm information about the product and process. All studies should be
planned and conducted according to sound scientific principles, appropriately
documented, and approved in accordance with the established procedure appropriate
for the stage of the lifecycle.
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 The terms attribute(s) (e.g., quality, product, component) and parameter(s) (e.g.,
process, operating, and equipment) are not categorized with respect to criticality in
this guidance. With a lifecycle approach to process validation that employs risk based
decision making throughout that lifecycle, the perception of criticality as a continuum
rather than a binary state is more useful. All attributes and parameters should be
evaluated in terms of their.
 Roles in the process and impact on the product or in-process material and reevaluated
as new information become available. The degree of control over those attributes or
parameters should be commensurate with their risk to the process and process output.
In other words, a higher degree of control is appropriate for attributes or parameters
that pose a higher risk. The Agency recognizes that terminology usage can vary and
expects that each manufacturer will communicate the meaning and intent of its
terminology and categorization to the Agency.
 Many products are single-source or involve complicated manufacturing processes.
Homogeneity within a batch and consistency between batches are goals of process
validation activities. Validation offers assurance that a process is reasonably protected
against sources of variability that could affect production output, cause supply
problems, and negatively affect public health.
Stage1. PROCESS DESIGN:
Process design is the activity of defining the commercial manufacturing process that will be
reflected in planned master production and control records. The goal of this stage is to design
a process suitable for routine commercial manufacturing that can consistently deliver a
product that meets its quality attributes.
Building and Capturing Process Knowledge and Understanding: Generally, early process
design experiments do not need to be performed under the cGMP conditions required for
drugs intended for commercial distribution that are manufactured during Stage 2 (process
qualification) and Stage 3 (continued process verification). They should, however, be
conducted in accordance with sound scientific methods and principles, including good
documentation practices. This recommendation is consistent with ICH Q10 Pharmaceutical
Quality System21. Decisions and justification of the controls should be sufficiently
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documented and internally reviewed to verify and preserve their value for use or adaptation
later in the lifecycle of the process and product.
Establishing a Strategy for Process Control:
Process knowledge and understanding is the basis for establishing an approach to process
control for each unit operation and the process overall. Strategies for process control can be
designed to reduce input variation, adjust for input variation during manufacturing (and so
reduce its impact on the output), or combine both approaches. Process controls address
variability to assure quality of the product. Controls can consist of material analysis and
equipment monitoring at significant processing points. Decisions regarding the type and
extent of process controls can be aided by earlier risk assessments, then enhanced and
improved as process experience is gained. FDA expects controls to include both examination
of material quality and equipment monitoring. Special attention to control the process
through operational limits and in-process monitoring is essential in two possible scenarios:
1. When the product attribute is not readily measurable due to limitations of sampling or
detectability (e.g., viral clearance or microbial contamination) or
2. When intermediates and products cannot be highly characterized and well-defined quality
attributes cannot be identified.
Stage2. PROCESS QUALIFICATION:
During the process qualification (PQ) stage of process validation, the process design is
evaluated to determine if it is capable of reproducible commercial manufacture. This stage
has two elements:
(1) Design of the facility and qualification of the equipment and utilities and
(2) Process performance qualification (PPQ). During Stage 2, cGMP-compliant procedures
must be followed. Successful completion of Stage 2 is necessary before commercial
distribution. Products manufactured during this stage, if acceptable, can be released for
distribution.
36
Design of a Facility and Qualification of Utilities and Equipment: Proper design of a
manufacturing facility is required under part 211, subpart C, of the cGMP regulations on
Buildings and Facilities. It is essential that activities performed to assure proper facility
design and commissioning precede PPQ. Here, the term qualification refers to activities
undertaken to demonstrate that utilities and equipment are suitable for their intended use and
perform properly. These activities necessarily precede manufacturing products at the
commercial scale.
Process Performance Qualification: The process performance qualification (PPQ) is the
second element of Stage 2, process qualification. The PPQ combines the actual facility,
utilities, equipment (each now qualified), and the trained personnel with the commercial
manufacturing process, control procedures, and components to produce commercial batches.
A successful PPQ will confirm the process design and demonstrate that the commercial
manufacturing process performs as expected. Success at this stage signals an important
milestone in the product lifecycle. A manufacturer must successfully complete PPQ before
commencing commercial distribution of the drug product. The decision to begin commercial
distribution should be supported by data from commercial-scale batches. Data from
laboratory and pilot studies can provide additional assurance that the commercial
manufacturing process performs as expected.
PPQ Protocol: A written protocol that specifies the manufacturing conditions, controls,
testing, and expected outcomes is essential for this stage of process validation. We
recommend that the protocol discuss the following elements:
 The manufacturing conditions, including operating parameters, processing limits, and
component (raw material) inputs.
 The data to be collected and when and how it will be evaluated.
 Tests to be performed (in-process, release, characterization) and acceptance criteria
for each significant processing step.
 The sampling plan, including sampling points, number of samples, and the frequency
of sampling for each unit operation and attribute. The number of samples should be
adequate to provide sufficient statistical confidence of quality both within a batch and
between batches. The confidence level selected can be based on risk analysis as it
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relates to the particular attribute under examination. Sampling during this stage
should be more extensive than is typical during routine production.
The criteria should include for process performance indicators,
 A description of the statistical methods to be used in analyzing all collected data (e.g.,
statistical metrics defining both intra-batch and inter-batch variability).
 Provision for addressing deviations from expected conditions and handling of
nonconforming data. Data should not be excluded from further consideration in terms
of PPQ without a documented, science-based justification.
Design of facilities and the qualification of utilities and equipment, personnel training and
qualification, and verification of material sources (components and container/closures), if not
previously accomplished.
PPQ Protocol Execution and Report: Execution of the PPQ protocol should not begin
until the protocol has been reviewed and approved by all appropriate departments, including
the quality unit. Any departures from the protocol must be made according to established
procedure or provisions in the protocol. Such departures must be justified and approved by all
appropriate departments and the quality unit before implementation. The commercial
manufacturing process and routine procedures must be followed during PPQ protocol
execution. The PPQ lots should be manufactured under normal conditions by the personnel
routinely expected to perform each step of each unit operation in the process. Normal
operating conditions should include the utility systems (e.g., air handling and water
purification), material, personnel, environment, and manufacturing procedures.
A report documenting and assessing adherence to the written PPQ protocol should be
prepared in a timely manner after the completion of the protocol. This report should:
• Discuss and cross-reference all aspects of the protocol.
• Summarize data collected and analyze the data, as specified by the protocol.
• Evaluate any unexpected observations and additional data not specified in the protocol.
38
• Summarize and discuss all manufacturing nonconformances such as deviations, aberrant
test results, or other information that has bearing on the validity of the process.
• Describe in sufficient detail any corrective actions or changes that should be made to
existing procedures and controls.
• State a clear conclusion as to whether the data indicates the process met the conditions
established in the protocol and whether the process is considered to be in a state of control. If
not, the report should state what should be accomplished before such a conclusion can be
reached. This conclusion should be based on a documented justification for the approval of
the process, and release of lots produced by it to the market in consideration of the entire
compilation of knowledge and information gained from the design stage through the process
qualification stage.
• Include all appropriate department and quality unit review and approvals.
Stage 3. CONTINUED PROCESS VERIFICATION:
The goal of the third validation stage is continual assurance that the process remains in a state
of control (the validated state) during commercial manufacture. A system or systems for
detecting unplanned departures from the process as designed is essential to accomplish this
goal. Adherence to the cGMP requirements, specifically, the collection and evaluation of
information and data about the performance of the process, will allow detection of undesired
process variability. Evaluating the performance of the process identifies problems and
determines whether action must be taken to correct, anticipate, and prevent problems so that
the process remains in control.
An ongoing program to collect and analyze product and process data that relate to product
quality must be established. The data collected should include relevant process trends and
quality of incoming materials or components, in-process material, and finished products. The
data should be statistically trended and reviewed by trained personnel. The information
collected should verify that the quality attributes are being appropriately controlled
throughout the process.
We recommend that a statistician or person with adequate training in statistical process
control techniques develop the data collection plan and statistical methods and procedures
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used in measuring and evaluating process stability and process capability. Procedures should
describe how trending and calculations are to be performed and should guard against
overreaction to individual events as well as against failure to detect unintended process
variability. Production data should be collected to evaluate process stability and capability.
The quality unit should review this information. If properly carried out, these efforts can
identify variability in the process and/or signal potential process improvements.
Good process design and development should anticipate significant sources of variability and
establish appropriate detection, control, and/or mitigation strategies, as well as appropriate
alert and action limits. However, a process is likely to encounter sources of variation that
were not previously detected or to which the process was not previously exposed. Many tools
and techniques, some statistical and others more qualitative, can be used to detect variation,
characterize it, and determine the root cause. We recommend that the manufacturer use
quantitative, statistical methods whenever appropriate and feasible. Scrutiny of intra-batch as
well as inter-batch variation is part of a comprehensive continued process verification
program under.
We recommend continued monitoring and sampling of process parameters and quality
attributes at the level established during the process qualification stage until sufficient data
are available to generate significant variability estimates. These estimates can provide the
basis for establishing levels and frequency of routine sampling and monitoring for the
particular product and process. Monitoring can then be adjusted to a statistically appropriate
and representative level. Process variability should be periodically assessed and monitoring
adjusted accordingly.
Variation can also be detected by the timely assessment of defect complaints, out-of-
specification findings, process deviation reports, process yield variations, batch records,
incoming raw material records, and adverse event reports. Production line operators and
quality unit staff should be encouraged to provide feedback on process performance. We
recommend that the quality unit meet periodically with production staff to evaluate data,
discuss possible trends or undesirable process variation, and coordinate any correction or
follow-up actions by production.
Data gathered during this stage might suggest ways to improve and/or optimize the process
by altering some aspect of the process or product, such as the operating conditions (ranges
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and set-points), process controls, component, or in-process material characteristics. A
description of the planned change, a well-justified rationale for the change, an
implementation plan, and quality unit approval before implementation must be documented.
Depending on how the proposed change might affect product quality, additional process
design and process qualification activities could be warranted.
Maintenance of the facility, utilities, and equipment is another important aspect of ensuring
that a process remains in control. Once established, qualification status must be maintained
through routine monitoring, maintenance, and calibration procedures and schedules.
CONCURRENT RELEASE OF PPQ BATCHES: In most cases, the PPQ study needs to
be completed successfully and a high degree of assurance in the process achieved before
commercial distribution of a product. In special situations, the PPQ protocol can be designed
to release a PPQ batch for distribution before complete execution of the protocol steps and
activities, i.e., concurrent release. FDA expects that concurrent release will be used rarely.
Concurrent release might be appropriate for processes used infrequently for various reasons,
such as to manufacture drugs for which there is limited demand (e.g., orphan drugs, minor
use and minor species veterinary drugs) or which have short half lives (e.g.,
radiopharmaceuticals, including positron emission tomography drugs). Concurrent release
might also be appropriate for drugs that are medically necessary and are being manufactured
in coordination with the Agency to alleviate a short supply.
A commercial manufacturing process can only be made after the PPQ protocol is fully
executed and the data are fully evaluated. If Stage 2 qualification is not successful (i.e., does
not demonstrate that the process as designed is capable of reproducible performance at
commercial scale), then additional design studies and qualification may be necessary. The
new product and process understanding obtained from the unsuccessful qualification study
(ies) can have negative implications if any lot was already distributed. Full execution of
Stages 1 and 2 of process validation is intended to preclude or minimize that outcome.
Circumstances and rationale for concurrent release should be fully described in the PPQ
protocol. Even when process performance assessment based on the PPQ protocol is still
outstanding, any lot released concurrently must comply with all CGMPs, regulatory approval
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requirements, and PPQ protocol lot release criteria. Lot release under a PPQ protocol is based
upon meeting confidence levels appropriate for each quality attribute of the drug.
When warranted and used, concurrent release should be accompanied by a system for careful
oversight of the distributed batch to facilitate rapid customer feedback. For example,
customer complaints and defect reports should be rapidly assessed to determine root cause
and whether the process should be improved or changed. Concurrently released lots must also
be assessed in light of any negative PPQ study finding or conclusions and appropriate
corrective action must be taken .We recommend that each batch in a concurrent release
program be evaluated for inclusion in the stability program. It is important that stability test
data be promptly evaluated to ensure rapid detection and correction of any problems
DOCUMENTATION: Documentation at each stage of the process validation lifecycle is
essential for effective communication in complex, lengthy, and multidisciplinary projects.
Documentation is important so that knowledge gained about a product and process is
accessible and comprehensible to others involved in each stage of the lifecycle. Information
transparency and accessibility are fundamental tenets of the scientific method. They are also
essential to enabling organizational units responsible and accountable for the process to make
informed, science-based decisions that ultimately support the release of a product to
commerce.
The degree and type of documentation required by cGMP vary during the validation
lifecycle. Documentation requirements are greatest during Stage 2, process qualification, and
Stage 3, continued process verification. Studies during these stages must conform to cGMPs
and must be approved by the quality unit in accordance with the. Viral and impurity
clearance studies, even when performed at small scale, also require quality unit oversight.
cGMP documents for commercial manufacturing (i.e., the initial commercial master batch
production and control record and supporting procedures are key outputs of Stage 1, process
design. We recommend that firms diagram the process flow for the full-scale process. Process
flow diagrams should describe each unit operation, its placement in the overall process,
monitoring and control points, and the component, as well as other processing material inputs
(e.g., processing aids) and expected outputs (i.e., in-process materials and finished product).
It is also useful to generate and preserve process flow diagrams of the various scales as the
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process design progresses to facilitate comparison and decision making about their
comparability.
ANALYTICAL METHODOLOGY: Process knowledge depends on accurate and precise
measuring techniques used to test and examine the quality of drug components, in-process
materials, and finished products. Validated analytical methods are not necessarily required
during product- and process-development activities or when used in characterization studies.
Nevertheless, analytical methods should be scientifically sound (e.g., specific, sensitive, and
accurate) and provide results that are reliable. There should be assurance of proper equipment
function for laboratory experiments. Procedures for analytical method and equipment
maintenance, documentation practices, and calibration practices supporting process-
development efforts should be documented or described. New analytical technology and
modifications to existing technology are continually being developed and can be used to
characterize the process or the product. Use of these methods is particularly appropriate when
they reduce risk by providing greater understanding or control of product quality. However,
analytical methods supporting commercial batch release must follow cGMPs. Clinical supply
production should follow the cGMPs appropriate for the particular phase of clinical studies.
QUALITY BY DESIGN AND THE NEW PROCESS VALIDATION GUIDANCE21:
Pilot Program: The International Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use (ICH) brings together regulatory
authorities and pharmaceutical companies from Europe, Japan, and the United States to
discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH
has worked through its global cooperation group to harmonize the increasingly global face of
drug development. Its mission is to help ensure that safe, effective, and high-quality
medicines are developed and registered with the most efficient use of resources. The
organization focuses on four main subjects: quality, safety, efficacy, and multidisciplinary
guidelines, which include the MedDRA standardized medical terminology guide and the
common technical document (CTD), a format for submitting information for regulatory
review in all participating countries. In relation to process validation, four ICH subtopics are
most relevant: Q8, Q9, Q10, and Q11.
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ICH Q8(R2): Pharmaceutical Development was adopted by the European Union in June
2009, by the United States in November 2009, and by Japan in June 2010, after having been
finalized in November 2005. This document is intended to provide guidelines for drug
products as defined in the scope of Module 3 of the common technical document (CTD),
which is ICH topic M4. The guideline does not apply to contents of submissions for drug
products in clinical research, but its principles are important to consider during that stage. An
annex to the tripartite harmonized ICH text was finalized in November 2008 and incorporated
into the core document, which was then, renamed Q8 (R1). That annex provided further
clarification of key concepts and described the principles of QbD. It showed how concepts
and tools (e.g., design space) outlined in the parent document could be put into practice.
When a company applies QbD and quality risk management as part of a pharmaceutical
quality system, opportunities arise to enhance science- and risk-based regulatory approaches
The Q8 guideline was revised to (R2) in the summer of 2009 to reflect minor corrections.
ICH Q9: Quality Risk Management was adopted by the European Union in January 2006, by
the United States in June 2006, and by Japan in September 2006 after the tripartite
harmonized ICH guideline was finalized in November 2005. This guideline provides
principles and examples of tools for quality risk management that can be applied to all
aspects of pharmaceutical quality including development, manufacturing, distribution, and
inspection and submission/review. It can be applied throughout the lifecycle of drug
substances and medicinal products, biological, and biotechnological products and covers the
use of raw materials, solvents, Excipients, packaging, and labeling materials.
ICH Q10: Pharmaceutical Quality System was adopted by the European Union in July 2008,
by the United States in April 2009, and by Japan in February 2010 after the tripartite
harmonized ICH guideline had been finalized in June 2008. This document applies to
pharmaceutical drug substances and drug products (including biotechnology and biological
products) throughout their lifecycles. Companies should apply its elements appropriately and
proportionately to each stage.
Other Documents: Real-world experiences of companies and regulators with the Q8, Q9,
and Q10 guidelines made ICH aware of a need for some clarification of key issues. The latest
version of its resulting questions-and-answers document was finalized in
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ISPE has published a guidance document that’s free for its members and available to
nonmembers at a nominal cost: ISPE Product Quality Lifecycle Implementation Guide:
Overview of Product Design, Development and Realization — A Science- and Risk-Based
Approach to Implementation International Society for Pharmaceutical Engineering.
According to ISPE:, the guide is “the first in a series of product quality lifecycle
implementation good practice guides that will describe enhanced, QbD approaches to product
realization and is an introduction to and an overview of the guides series.” To address
product and process development, transfer to and establishment of commercial manufacture
using science- and risk-based approaches, the series will cover critical quality attributes
(CQAs) and critical process parameters (Cops), design space, and control strategy.
In addition, ASTM International has published a standard that supports ICH Q8 and Q9 titled
ASTM E2537-08: Standard Guide for Application of Continuous Quality Verification to
Pharmaceutical and Biopharmaceutical Manufacturing. According to ASTM, “The
accumulated product and process understanding used to identify critical quality attributes
(CQAs), together with the knowledge that the risk-based monitoring and control strategy will
enable their control, should provide confidence to show validation of each batch
manufactured — as opposed to a conventional discrete process validation effort.”
ICH Q11: Development and Manufacture of Drug Substances was endorsed as a topic by the
ICH Steering Committee in April 2008. This new guidance is proposed for active
pharmaceutical ingredients (APIs) harmonizing the scientific and technical principles relating
to the description and justification of the development and manufacturing process (common
technical document sections of drug substances including both chemical and
biotechnological/biological entities. The document is only at stage 1 of the ICH process
currently other Guidance Document molecules.
The pilot program has provided an opportunity for the biopharmaceutical industry and the
FDA to evaluate and identify best practices for key QbD elements of target product profiles,
critical quality attributes (CQA), risk assessment, process characterization for design-space
definition, CQA-focused control strategies, and expanded change protocols. This builds on
the concept of well-characterized biological (a.k.a. specified biologics), which came about in
the late 1990s when it was recognized that analytical methods had improved to the point at
which biologics could be analyzed and described well enough to separate their identities from
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their processes. A few years later, CDER took over responsibility for those well-
characterizable products from the Center for Biologics Evaluation and Research (CBER).
The OBP pilot program offers individualized examination of QbD initiatives submitted in
market applications for biotech therapies for a number of original and supplemental biologic
license and new drug applications. Manufacturers — such as Genentech, an early program
participant — voluntarily provide chemistry, manufacturing, and controls (CMC) information
in an expanded change protocol describing their implementation of QbD and risk
management. Their candidate products are monitored by the OBP throughout product
development and testing after early discussions with FDA reviewers about R&D issues.
For the pilot, the Office of Compliance (OC) will be part of review communication, so there
is a need to transfer information among OBP, OC, and the field. Ideally, product reviewers
should be present at initial QbD-type inspections. The Office of Compliance will play a key
role in understanding the role of quality systems in QbD filings and their control strategies.
Continuous Verification: According to Swann, the new guidance describes three stages of
process validation during the lifecycle of a drug product, which falls into line with ICH Q8
during early product and process development, process design builds criteria for testing,
qualification, and setting specifications later on. “The commercial manufacturing process is
defined during this stage based on knowledge gained through development and scale-up
activities” Process qualification encompasses many validation concepts familiar to those who
have been working with the previous guidance document all along: Manufacturing
equipment, tooling, and instrumentation, and utilities must be qualified using standard
validation protocols along with an associated validation master plan, risk assessment, and
requirements specifications. “During this stage, the process design is evaluated to determine
if the process is capable of reproducible commercial manufacturing.
Continued process verification, the final stage, was the focus of Grace McNally’s
presentation. “Ongoing assurance is gained during routine production that the process
remains in a state of control” McNally emphasized the “life-cycle approach” that makes
process validation an ongoing activity — not something a company can do and then move on.
“Criticality” (as of quality attributes) is a continuum, she pointed out, not an either–or
question. McNally also pointed to several other sections of the Code of Federal Regulations
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that can help those working to implement these concepts into their manufacturing process
development
CURRENT TRENDS OF PROCESS VALIDATION22,23,24:
The significance of the process validation has taken on a new emphasis, since a series of new
rules and regulations on this subject have been published, notably
 EU GMP Guide Annex 15: Qualification and Validation
 EMA Note for Guidance on Process Validation
 FDA Guidance for Industry -Process Validation: General Principles and Practices
Last but not least, EU GMP Guide, Part II covers the topic of validation more extensively
than most other rules or regulations. For Excipients, the topic of validation is described in the
IPEC Good Manufacturing Practices Guide for Bulk Pharmaceutical Excipients.
The objective of the EMA Note for Guidance on Process Validation is standardization of the
validation documents that must be submitted with the submission file for marketing
authorization. This guideline is directed at manufacturers of pharmaceutical products; to
some extent, though, the procedure is also transferable to the manufacture of active
pharmaceutical ingredients, Excipients, biotech or blood products.
The EMA Note for Guidance on Process Validation is to be revised in the course of 2011 in
order to incorporate the concepts of ICH Q8, Q9 and Q10. The objective here is primarily to
consolidate the various concepts and to clarify questions resulting from this -but not to
introduce novel requirements. No additional requirements will result from this for products
which have already been approved.
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LITERATURE REVIEW
 Jyotsna godbole et al.,25designed the concept of bilayer matrix tablets containing
Acarbose as immediate release component using sodium starch glycolate and cross
croscarmellose sodium as super disintegrating agent and Metformin hydrochloride
(HCl) for sustained release component by using hydroxyl propyl methyl cellulose
(HPMC K 4M), (HPMC K 100) and sodium carboxyl methyl cellulose (SCMC) as the
matrix forming polymer and PVPK-30 as binder. Matrix tablet are the type of
controlled drug delivery systems, which release the drug in continuous manner. These
release the drug by both as well as diffusion controlled mechanisms metformin HCl is
6.2 hrs, so an attempt was made in the direction of preparation and optimization of a
combination of sustained release and immediate release in a single tablet. Tablets
were prepared by wet granulation and direct compression method. Tablets were
evaluated for post compression parameters. The tablets were evaluated for physico-
chemical property. All the values were found to be satisfactory. Invitro release studies
were carried as per USP in water and phosphate buffer of pH 6.8 using the apparatus
I. The final preparation showed release of drug up hours. FTIR studies revealed that
there is no interaction between the drug and other excipients used in the study.
 Kwabena ofori-kwakye et al.,26 carried out study of the in vitro behaviour of tablet
cores coated with novel films of albizia, albizia/khaya and albizia/HPMC. Diclofenac
sodium tablet cores, 225 mg, were formulated and coated with aqueous film
formulations consisting of albizia gum only, albizia/khaya (25:75), and albizia/HPMC
(90:10). The thickness, breaking strength, disintegration time, swelling index and
drug release properties of the uncoated and film coated tablets were evaluated. Tablet
thickness increased with increase in coating time. The breaking strength of the film
coated tablets was higher than that of the tablet cores and increased with increase in
coating time. The disintegration time of the uncoated and film coated tablets in the
media used was pH‐ dependent and followed the rank order: 0.1 M HCl > pH 6.8
phosphate buffer > distilled water. The extent of swelling (water absorption) of the
film coated tablets in 0.1 M HCl was dependent on film composition and followed
the order: albizia/HPMC > albizia > albizia/khaya. Drug release in pH 6.8 phosphate
buffer was faster than in 0.1 M HCl solution. Albizia and albizia/HPMC film coated
tablets exhibited the slowest drug release in the acidic and basic media, respectively.
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The study shows the potential of albizia, albizia/khaya and albizia/HPMC films as
coating materials for tablets.
 Vandana B. Patel et al,.27 studied prospective process validation of Cimtidine 400mg
tablet dosage form and investigated that Quality cannot be adequately assured by in-
process and finished inspections and testing but it should be built in to the
manufacturing process. These processes should be controlled in order that the finished
product meets all quality specifications. Therefore building of quality requires careful
attention to a number of factors, such as the selection of materials, product and
process design, control variables, in process control and finished product testing. The
critical process parameters were identified with the help of process capability and
evaluated by challenging its lower and upper release specifications. Three initial
process validation batches of same size, method, equipment & validation criteria were
taken. The critical parameter involved in sifting, dry mixing, preparation of
granulating agent, wet mixing, wet milling, drying, sizing, lubrication & compression
stages were identified and evaluated as per validation plan. Film coating of tablet
were evaluated for coating uniformity, coating process efficiency and surface
roughness. The spry rate ,atomization air pressure, distance of nozzle from tablet bed,
inlet air temperature, pan differential pressure ,pan speed and % solid content these
affect the final film quality of coated tablets. The outcome indicated that this process
validation data provides high degree of assurance that manufacturing process
produces product meeting its predetermined specifications and quality attributes.
 Raveendranath Thaduvai et al.,28 formulated Sodium Pantoprazole-Loaded Enteric
Micro particles Prepared by Spray Drying and studied the effect of the Scale of
Production and Process Validation. In this study investigation of the physical
characteristics were carried out for enteric pantoprazoleloaded micro particles
prepared by spray drying using a blend of Eudragit and HPMC. At pilot scale, among
the four sets of micro particles prepared varying the atomization and the air pressure,
in three of them free micro particles were obtained. The micro particles prepared with
rotating disc atomizer or two fluid atomizer and mixed flow presented either crystals
on the particle surface or very high polydispersity, respectively. Using two fluid
nozzle and air pressure of 49 kPa (N1-microparticles) the product obtained was not
adequate because it presented strings in the powder. Using the same atomizer but air
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pressure of 196 kPa (N2-microparticles) the micro particles presented high
encapsulation efficiency and the highest stabilization of formulation in acid medium.
N2-microparticles were chosen for the pilot scale evaluation. The three batches of
pantoprazole-loaded micro particles prepared to validate the process showed
reproducible diameter, polydispersity, densities, encapsulation efficiency and gastro-
resistance profile.
 Rahul Paruchuri et al.,29 have studied that validation is one of the important steps in
achieving and maintaining the quality of the final product. If each step of production
process is validated, it can be assured that the final product is of the best quality and
validation of the individual steps of the processes is called the process validation.
Different dosage forms have different validation protocols. Here this article
concentrates to provide assurance that the manufacturing procedure is suitable for
intended purpose and consistently meet predetermined specifications and quality
attributes, as per specified master formula record. It also provides a documented
evidence for the operation sequence and schedule of manufacturing process and to
determine the critical parameters and variables in the process of manufacturing of the
tablets. It gives a higher degree of assurance that the manufacturing process
consistently meet the pre-determined specifications and quality products output can
be used to increase productivity, its consistent quality and decreasing the need for
processing/market complaints.
 Jignakumari Manubhai Tandel etal.,30 have studied that validation is best viewed as
an impartment and integral part of cGMP, validation is therefore one element of
quality assurance programs associated with a particular process. Then word validation
simply means “assessment of validity” or action of proving effectiveness. This
process involves addition of granulating agent to the dry mixed material and
converting into granules. The goal of quality system is to consistently produce
products that are suitable for their intended use. Process validation is a key element in
assuring that these principles and goals are met. In this study concurrent process
validation was carried out for pyrazinamide tablets IP 750 mg. In tablet dosage form,
critical parameters like dry mixing, granulation, drying, sifting and milling,
lubrication and compression were taken up for validation studies. In-process quality
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monitoring of all critical processing steps was done for three production batches.
LOD of the dried, milled and lubricated granules were checked and found within the
limit. Assay after lubrication was within the specified limit, indicating blend
uniformity. Physical parameters, dissolution and assay were checked and results
found within the acceptance criteria. During packing operation, blisters were checked
and found satisfactory. Thus process validation of pyrazinamide tablets IP 750 mg
was successfully completed and found within the specifications.
 Ruchita.v.kumar et al.,31 studied the potential of a novel combination of a
galactomannan with acarbose (100 mg) that  was evaluated for attaining a desired
hypoglycaemic effect over a prolonged period of time. Three major antidiabetic
galactomannans viz., fenugreek gum, boswellia gum, and locust bean gum were
selected in order to achieve a synergistic effect in the treatment alongwith retardation
in drug release. In vitro studies indicated that batches containing various proportions
of fenugreek gum (AF40-60) were able to control drug release for a longer duration of
approximately 10–12 h. In contrast, the matrices prepared using boswellia and locust
bean gum were able to sustain the release for relatively shorter durations. Drug
release mainly followed first-order release kinetics owing to the highly soluble nature
of the drug. In vivo study depicted a significant reduction (p < 0.001) in the
postprandial blood glucose and triglyceride levels in the diabetic rats on treatment
with formulation AF40. Thus, the developed system provides a better control of the
postprandial glycaemic levels and it also obviates the need of conventional multiple
dosing of acarbose. Furthermore, it also reduces the occurrence of side effects like
diarrhea and loss of appetite.
 F. A. Ibrahim et al.,32 have studied a simple and sensitive kinetic spectrophotometric
method for the determination of acarbose and miglitol in bulk and in their
pharmaceutical preparations using alkaline potassium permanganate as an oxidizing
agent. The method involves determination of acarbose and miglitol by kinetic studies
of their oxidation at room temperature for a fixed time of 15 minutes for acarbose and
25 minutes for miglitol. The absorbance of the colored manganate ion was measured
at 610 nm. Alternatively, the kinetic decrease in the absorbance of permanganate
upon addition of the studied drugs at 525 nm was also used. The absorbance versus
concentration plot was rectilinear over the concentration range of 4 - 20 and 1-10 μg/
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ml for acarbose and miglitol, respectively. The detection limits were 0.189 and 0.089
μg/ ml at 610 nm and 0.081 and 0.179 μg/ ml at 525 nm for acarbose and miglitol
respectively. The method was successfully applied for the determination of these
drugs in their dosage forms. The results obtained were in good agreement with those
obtained with the reference methods.
 Kumari G et al.,33 Formulated and studied  release kinetics of Hydrogel containing
Acarbose using polymers as Hydroxypropylmethyl cellulose and Guar gum by Wet
granulation technique. Hydrogel matrix tablets of Acarbose were formulated using
these polymers which, slows the release of Acarbose over a period of 12 h and were
suitable for maintenance portion of oral controlled release tablets. Acarbose release
from these tablets was diffusion controlled and followed zero order kinetics after a lag
time of 1 h and It was concluded that drug release rate was inversely proportional to
the concentration of retardant polymer i.e., increase in concentration of retardant
polymer resulted in a reduction in the drug release rate.
 Pradeep kumar T et a.,l34 developed a pharmaceutically equivalent, stable, cost
effective and quality improved formulation of film coated Ticlopidine Hcl tablets by
direct compression method. The three superdisintegrants used in the study were
crosscaramellose soudium(CCS), MCC, and native Starch. The formulation containg
combination of ccs,mcc and native starch (6,44.73,554.75 mg) showed minimum DT
and maximum drug realase.
 Nasiruddin Ahmad Farooqui et al.,35 developed film coated tablets of senidazole
which are designed to rupture and expose core tablets at the desired location in the
gastro intestinal track the coating is done by film coating solutions which are
polymers in nature, forming smooth coat over core tablets. The present study was
aimed to formulate film coated tablets of senidazole by wet granulation and the
granules are compressed for tablets and they are coated with polymers for getting film
coated tablets at specified conditions and the evaluation for the following parameters
as average weight, weight variation, thickness, dissolution, related substance,
disintegration time and assay for compliance with acceptance criteria for formulation
of secnidazole film coated tablets.
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AIM AND OBJECTIVE OF WORK
 To formulate and evaluate the Pre-formulation and Pre-compression parameters of
Acarbose core tablet.
 To formulate and evaluate Acarbose film coated tablets using various methods and
various excipient.
 To carry out the process validation studies of the formulated Acarbose tablets.
 To carry out process validation studies for the three batches formulated.
Batch A
Batch B
Batch C.
 To maintain the quality of the prepared product.
 The scope of this project is to minimize the errors in the process validation.
 To find out the uniformity in the batches.
 To check whether the Equipments that are used must justify the parameters that is in
the specifications.
 To maintain the process validation control variables such as the analytical procedure,
equipments, production process.
 To find out the results that are obtained is within the acceptance criteria.
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PLAN OF WORK
The study was planned to carry out as follows,
1. Literature survey.
2. Checking out for drug and excipient compatibility by FT-IR studies.
3. Preparation of blend of drug and excipients.
4. Pre compression studies which include,
a) Angle of Repose
b) Bulk Density
c) Tapped Density
d) Compressibility Index
e) Hausner’s Ratio.
5. Preparation of Acarbose tablets by using the optimized formula.
6. Evaluation of the Acarbose core tablets.
i. Weight variation test
ii. Hardness test
iii. Thickness test
iv. Friability test
v. Disintegration time
7. Validation of the tablets and process.
8. Film coating of best Acarbose core tablets and packing.
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DRUG PROFILE:
ACARBOSE36
Other Names:- Precose,  Prandase.
STRUCTURE OF ACARBOSE
MOLECULAR FORMULA: C25H43NO18.
MOLECULAR WEIGHT: 645.605
CHEMICAL NAME: 2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5- {[(2R,3R,4S,5S,6R)-3,4-
dihydroxy-6-methyl- 5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3- (hydroxymethyl)cyclohex-2-en-
1-yl]amino} tetrahydro-2H-pyran-2-yl]oxy}-3,4-dihydroxy- 6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yl]oxy}- 6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol.
APPEARANCE: White to yellowish, amorphous powder hygroscopic.
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SOLUBILITY: Very soluble in water, Soluble in Methanol, Practically insoluble in
Methylene chloride
CATEGORY OF DRUG:
 Hypoglycemic agent.
 Enzyme inhibitor.
MECHANISM OF ACTION:
Acarbose inhibits enzymes (glycoside hydrolases) needed to digest carbohydrates,
specifically, alpha-glucosidase enzymes in the brush border of the small intestines and
pancreatic alpha-amylase. Pancreatic alpha-amylase hydrolyzes complex starches to
oligosaccharides in the lumen of the small intestine, whereas the membrane-bound intestinal
alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose
and other monosaccharides in the small intestine. Inhibition of these enzyme systems reduces
the rate of digestion of complex carbohydrates. Less glucose is absorbed because the
carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-
term effect of these drugs therapies is to decrease current blood glucose levels; the long-term
effect is a reduction in HbA1c level. This reduction averages an absolute decrease of 0.7%,
which is a decrease of about 10% in typical HbA1c values in diabetes studies.
PHARMACOKINETICS:
Absorption
Less than 2% of an oral dose of acarbose was absorbed as active drug, while approximately
35% of total radioactivity from a 14C-labeled oral dose was absorbed. An average of 51% of
an oral dose was excreted in the feces as unabsorbed drug-related radioactivity within 96
hours of ingestion. Because acarbose acts locally within the gastrointestinal tract, this low
systemic bioavailability of parent compound is therapeutically desired. Following oral dosing
of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity
were attained 14 to 24 hours after dosing, while peak plasma concentrations of active drug
were attained at approximately one hour. The delayed absorption of acarbose-related
radioactivity reflects the absorption of metabolites that may be formed by either intestinal
bacteria or intestinal enzymatic hydrolysis.
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Metabolism
Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal
bacteria, but also by digestive enzymes. A fraction of these metabolites (approximately 34%
of the dose) was absorbed and subsequently excreted in the urine. The major metabolites
have been identified as 4-methylpyrogallol derivatives .One metabolite (formed by cleavage
of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity. This
metabolite, together with the parent compound, recovered from the urine, accounts for less
than 2% of the total administered dose. Bioavailability is very low.
Excretion
The fraction of acarbose that is absorbed as intact drug is almost completely excreted by the
kidneys. When acarbose was given intravenously, 89% of the dose was recovered in the urine
as active drug within 48 hours. In contrast, less than 2% of an oral dose was recovered in the
urine as active (i.e., parent compound and active metabolite) drug.This is consistent with the
low bioavailability of the parent drug. The plasma elimination half-life of acarbose activity is
approximately 2 hours in healthy volunteers. Consequently, drug accumulation does not
occur with 3 times a day oral dosing.
CLINICAL PHARMACOLOGY
Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates,
thereby resulting in a smaller rise in blood glucose concentration following meals. As a
consequence of plasma glucose reduction, acarbose reduces levels of glycosylated
hemoglobin in patients with type 2 diabetes mellitus. Systemic non-enzymatic protein
glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average
blood glucose concentration over time.
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ADVERSE EFFECTS:
 Since Acarbose prevents the degradation of complex carbohydrates into glucose,
some carbohydrate will remain in the intestine and be delivered to the colon.
 In the colon, bacteria digest the complex carbohydrates, causing gastrointestinal side-
effects such as flatulence (78% of patients) and diarrhea (14% of patients).
 Since these effects are dose-related, in general it is advised to start with a low dose
and gradually increase the dose to the desired amount.
 One study found that G.I. side effects decreased significantly (from 50% to 15%) over
24 weeks, even on constant dosing.
 Hepatitis has been reported with acarbose use. It usually goes away when the
medicine is stopped.
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EXCIPIENTS PROFILE37-45
MICROCRYSTALLINE CELLULOSE
Synonym : Cellulose gel, Crystalline Cellulose, Emocel, Fibrocel.
Chemical Name : Cellulose
Empirical formula : (C6H10O5)n where n = 220
Molecular weight : 36000
Description : MCC is purified, partially depolymerized cellulose that
occur is as a white, odorless, crystalline powder
composes of porous   particle. It commercially available
in different particle size and moisture grades that have
different properties and application.
Functional category : Adsorbent,  suspending agent, diluents,  disintegrants.
Applications : Microcrystalline cellulose is widely used as a wet-
binder/diluent in oral tablet and capsule formulations
where it is used in both granulation and direct
compression processes. In addition it is used as a
microcrystalline cellulose also has some lubricant and
disintegrant properties that make it useful in tableting.
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COLLOIDAL SILLICON DIOXIDE
Synonym : Aerosil 200; Amorphous
Fumed Silica; Aerosil90
Chemical Formula : SIO2
Molecular Weight : Not available.
Physical state and appearance : Solid. (Powdered solid.)
Odour : Odorless.
Taste : Tasteless.
Color : White.
Functional Category : Adsorbent. anticaking agent,emulsion thermal
Stabilizer glidant, suspending agent, tablet
disintegrant, stabilizer,viscosity-increasing
agent.
Applications : It gives desirable flow characters and improves
the flow properties of dry powders used in a
number of processes such as tableting and
capsule filling. It is also used to stabilize
emulsions and as a thixotropic thickening and
suspending agent in gels and semisolid
preparations.
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MAGNESIUM STEARATE
Synonyms : Magnesium octadecananoate,Octadecanoic acid, Magnesiusalt,
Stearic acid,magnesium salt.
Chemical name : Octadecanoic acid magnesium salt
Description : Magnesium stearate is a fine, white, precipitated or milled,
Impalpable powder of low bulk density, having a faint
odor or and a characteristic taste. The powder is greasy to the
touch and readily adheres to the skin
Empirical formula : C36H7OMg04
Molecular weight : 591.34
Functional Category : Tablet and capsule lubricant.
Application : Magnesium stearate is widely used in cosmetics, foods, and
pharmaceutical formulations. It is primarily used as a lubricant
in capsule and tablet manufacturing. It is also used in barrier
creams
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HYDROXY PROPYL METHYL CELLOLOSE
Synonyms : Benecel, HPMC, Methocel. ,Hypromellose
Chemical Name : Cellulose Hydroxy propyly methyl ether
Empirical formula : CH3 CH2 (OH) CH3
Description : white or creamy white fibrous or granular,
odorless, tasteless.
Melting point : Browns at 190-200 oC  Chars at 225-230 oC
Applications : To retard the release of drugs from a matrix in
tablets and capsules.
Also used as binder and in tablet coating.
Functional Category : Bioadhesive material; coating agent; controlled-
release agent; dispersing agent; dissolution
enhancer; emulsifying agent; emulsion
stabilizer; extended-release agent; film-forming
agent; foaming agent; granulation aid; modified
release agent; mucoadhesive; release-modifying
agent; solubilizing agent; stabilizing agent;
suspending agent; sustained-release agent; tablet
binder; thickening agent; viscosity-increasing
agent.
Applications : Hypromellose is widely used in oral,
ophthalmic, nasal, and topical pharmaceutical
formulations. In oral products, hypromellose is
primarily used as a tablet binder, in film coating,
and as a matrix for use in extended release tablet
formulations.  High-viscosity grades may be
used to retard the release of drugs from a matrix
in tablets and capsules. Hypromellose is also
used in liquid oral dosage forms as a suspending
and/or thickening agent.
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TALC
Synonym : Kerolite,  Magnesium Talc, Soapstone
Empirical formula : Mg3Si4O10(OH)2
Molecular weight : 379.27 Gm.
Category : Sillicate mineral.
Description : Talc is a very fine, white to grayish-white, odorless,
impalpable, crystalline powder. It adheres readily to the skin
and is soft to the touch and free from grittiness
Applications : Talc was once widely used in oral solid dosage formulations as
a lubricant and diluents . It is widely used as a dissolution
retardant in the development of controlled-release products.
Talc is also used as a lubricant in tablet formulations in a novel
powder coating for extended-release pellets and as an adsorbant
In topical preparations, talc is used as a dusting powder,
although it should not be used to dust surgical gloves.
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CORN STARCH
Synonyms : Amido,midon, amilo,amylum
Chemical Name : Starch
Empirical Formula : C6H10O5
Functional Category : Diluent, disintegrant, binder,
Description : Starch occurs as an odorless and tasteless, fine, white to off
White powder. It consists of very small spherical or ovoid
granules or grains whose size and shape are characteristic for
each botanical variety.
Applications : Starch is a versatile excipient used primarily in oral solid-
dosage formulations where it is utilized as a binder, diluent,and
disintegrant. As a diluent, starch is used for the preparation of
standardized triturates of colorants, potent drugs, and herbal
extracts, facilitating subsequent mixing or blending processes
in manufacturing operations. Starch is also used in dry-filled
capsule formulations for volume adjustment of the fill
matrix,and to improve powder flow, especially when using
dried starches. Starch acts as an antiadherent and lubricant in
tableting and capsule filling. In tablet formulations, freshly
prepared starch paste used as a binder for wet granulation.
Starch is one of the most commonly used tablet disintegrants.
64
TITANIUM DIOXIDE
Synonyms : Anatase titanium dioxide,brookite titanium dioxide, titanic
Anhydride,  titanii dioxidum, Tronox.
Chemical Name : Dioxotitanium
Empirical Formula : TiO2
Molecular Weight : 79.88
Functional Category : Coating agent; opacifier; pigment.
Description : White, amorphous, odorless, and tasteless nonhygroscopic
powder.Titanium dioxide may occur in several different
crystalline forms
Applications : Titanium dioxide is widely used  in topical and oral
pharmaceutical formulations as a white pigment. Owing to its
high refractive index, titanium dioxide has light scattering
properties that may be exploited in its use as a white pigment
and opacifier. In pharmaceutical formulations, titanium dioxide
is used as a white pigment in film-coating suspensions, sugar-
coated tablets, and gelatin capsules Titanium dioxide is also
used in dermatological preparations and cosmetics, such as
sunscreens.
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PROPYLENE GLYCOL
Synonyms : 1,2-Dihydroxypropane,2-hydroxypropanol; methyl ethylene
glycol; methyl glycol; propane-1,2-diol; propylenglycolum.
Chemical Name : 1,2-Propanediol
Empirical Formula : C3H8O2
Molecular Weight : 76.09
Description : Propylene glycol is a clear, colorless, viscous, practically
odourless liquid, with a sweet, slightly acrid.
Functional Category : Antimicrobial preservative; disinfectant; humectant; plasticizer;
solvent; stabilizing agent; water-miscible cosolvent.
Applications : Propylene glycol has become widely used as a solvent,
extractant, and preservative in a variety of parenteral and
nonparenteral pharmaceutical formulations. Propylene glycol is
commonly used as a plasticizer in aqueous film-coating
formulations.
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POLYETYLENE GLYCOL 6000
Synonyms : Carbowax,macrogola, PEG,
Chemical Name : a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl)
Empirical Formula : HOCH2(CH2OCH2)mCH2OH where m represents the average
number of oxyethylene groups.
Description : polyethylene glycol is being an addition polymer of ethylene
oxide and water. Polyethylene glycol grades 200–600 are
liquids; grades 1000 and above are solids at ambient
temperatures. Liquid grades (PEG 200–600) occur as clear,
colourless or slightly yellow-coloured, viscous liquids. They
have a slight but characteristic odor and a bitter, slightly
burning taste. PEG 600 can occur as a solid at ambient
temperatures. Solid grades (PEG>1000) are white or off-white
in color, and range in consistency from pastes to waxy flakes.
They have a faint, sweet odor. Grades of PEG 6000 and above
are available as free flowing milled powders.
Applications : Polyethylene glycols (PEGs) are widely used in a variety of
pharmaceutical formulations, including parenteral, topical,
ophthalmic, oral, and rectal preparations. Polyethylene glycols
are useful as ointment bases. Mixtures of polyethylene glycols
can be used as suppository Bases.
Functional Category : Ointment base; plasticizer; solvent; suppository base; tablet and
capsule lubricant.
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MATERIALS AND METHODS
LIST OF EQUIPMENTS
Table no :2 List of equipments
S.no EQUIPMENT NAME MODEL AND MAKE
1 Sifter GANSONS, MUMBAI.
2 Rapid Mixer Granulator GANSONS,MAHARASTRA.
3 Multimill SAMS TECHNO, MUMBAI.
4 Tray Drier SAMS TECHNO, MUMBAI.
5 Cage Blender R.P.PRODUCTS, MUMBAI.
6 Tablet Compression Machine CADMACH, AHAMADABAD.
7 Conventional Coating Machine SAMS TECHNO, MUMBAI.
8 Strip Packing Machine SATELLITE ENGINEERING,
MAHARASTRA.
9 Weighing Balance ESSAE TERA OKA,
MUMBAI.
10 High performance liquid
chromatography
WATERS.
11 IR Spectrophotometer JASCO.
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LIST OF RAW MATERIALS
Table No:3 List of Materials used:
S.NO NAME OF RAW MATERIAL SOURCE
1 ACARBOSE BIOCON LABORATARY PVT LTD,
INDIA.
2 CORN STARCH B-PURA LABORATY,CHENNAI.
3 MICRO CRYSTALLINE
CELLULOSE
(COMPRECEL M 101)
DFE PHARMA,CUDDALORE.
4 ISOPROPYL ALCHOHOL # RANBAXY FINE
CHEMICALS,CHENNAI.
5 COLLOIDAL SILLICON
DIOXIDE (AEROSIL 200)
CADSMAHAR,SALEM.
6 MAGNESIUM STEARATE COVITIEN NALLIM CHRODIT
GLOSA,INDIA.
7 CORN STARCH BPURA LABORATY,CHENNAI.
8 CORN STARCH BPURA LABORATY,CHENNAI.
9 HYDROXYPROPYL
METHYLCELLULOSE E15
TAIAN RUITAL CELLULOSE,CO
LTD,CHINA.
10 TALC TAIAN RUITAL CELLULOSE,CO
LTD,CHINA
11 TITANIUM DIOXIDE ROHA DYE CHEMICAL,PVT
LTD,DHABAR.
12 PROPYLENE GLYCOL B-PURA LABORATRY, CHENNAI.
13 POLYETYLENE GLYCOL
6000
B-PURA LABORATRY, CHENNAI.
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PREFORMULATION STUDIES
Drug-Excipient Compatibility Studies46
Fourier Transform Infrared Spectroscopy (FTIR):47
The Compatibility studies provide the scheme for the drug combination with excipients in the
fabrication of dosage form. The study was carried out to establish that the therapeutically
active drug has not undergone any changes after it has been subjected to processing steps
during formulation of tablets. Compatibility studies are carried out by mixing a different
proportion of Acarbose and Corn Starch, Micro Crystalline Cellulose, Colloidal Silica gel,
Magnesium Stearate.
The FTIR analysis was conducted for the structure characterization. FTIR spectra of the pure
drug, pure polymers and mixture of both were recorded. Formulations were taken in a Kbr
pellet using JASCO FTIR instrument. Approximately 5mg of samples were mixed with
50mg of spectroscopic grade Kbr; samples were scanned in the IR range from 650 to 3800
cm-1, with a resolution of  4cm-1.
Preparation of standard curve for Acarbose:
Accurately weigh and transfer 50mg of Acarbose working standard into 100ml clean, dry
volumetric flask and add about 50ml of water and dissolve. Dilute to volume with water and
mix.
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Formulation of Acarbose tablets.
Table No: 4 Formula for Acarbose immediate release tablets.
#does not appear in the final product.
FOR F1 & F2: DIRECT COMPRESSION
Formulation of Acarbose immediate release tablets was done by direct compression method.
 Sifting: Acarbose, Corn Starch and Micro Crystalline Cellulose are sifted through SS
sieve #60 fitted with vibratory sifter and collected in double polythene lined
HDPE/SS container.
Sift Aerosil 200, Corn Starch and magnesium stearate through SS sieve #40 in
vibratory sifter and collect in double polythene lined HDPE/SS container.
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8
Acarbose 50 50 50 50 50 50 50 50
Corn Starch 60 20 20 40 - 20 20 20
PVP K 30 - - - - 40 20 - -
Micro Crystalline Cellulose
PH 101/Comprecel M 101
20 40 60 40 40 40 60 60
Colloidal Silicon Dioxide
(Aerosil 200)
25 35 25 25 25 25 25 25
Magnesium Stearate 10 20 10 10 10 10 10 10
Purified Water # - - - - - - qs -
IsoPropyl Alcohol # - - - - - -- - qs
Total 165 165 165 165 165 165 165 165
71
Sift Micro Crystalline Cellulose, Corn Starch, Aerosil 200 through SS sieve #60 fitted
with vibratory sifter and collected in double polythene lined HDPE/SS container.
Sift Magnesium Stearate through SS sieve #80 fitted with vibratory sifter and
collected in double polythene lined HDPE/SS container.
 Blending/Lubrication: All the materials are blended for uniformity and then,
lubricated with collided silicon dioxide and magnesium stearate.
 Compression: The lubricated blend is compressed into tablets.
The quantity of glidant and lubricant were increased in the formulation to improve the flow
properties during compression and the next trial was done by direct compression.
Formulation of Acarbose immediate release tablets was done by direct compression method.
 Sifting: Acarbose, Corn Starch and Micro Crystalline Cellulose are sifted through SS
sieve #60 fitted with vibratory sifter and collected in double polythene lined
HDPE/SS container.
Sift Aerosil 200, Corn Starch and magnesium stearate through SS sieve #40 in
vibratory sifter and collect in double polythene lined HDPE/SS container.
Sift Micro Crystalline Cellulose, Corn Starch, Aerosil 200 through SS sieve #60 fitted
with vibratory sifter and collected in double polythene lined HDPE/SS container.
Sift Magnesium Stearate through SS sieve #80 fitted with vibratory sifter and
collected in double polythene lined HDPE/SS container.
 Blending/Lubrication: All the materials are blended for uniformity and then,
lubricated with collided silicon dioxide and magnesium stearate.
 Compression: The lubricated blend is compressed into tablets.
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GRANULATION:
Comparatively, dry granulation is less expensive and cost effective and much preferred than
wet granulation. So, dry granulation is chosen.
DRY GRANULATION:
 Sifting: Acarbose, Corn Starch and Micro Crystalline Cellulose are sifted through SS
sieve #60 fitted with vibratory sifter and collected in double polythene lined
HDPE/SS container.
Sift Aerosil 200, Corn Starch and magnesium stearate through SS sieve #40 in
vibratory sifter and collect in double polythene lined HDPE/SS container.
Sift Micro Crystalline Cellulose, Corn Starch, Aerosil 200 through SS sieve #60 fitted
with vibratory sifter and collected in double polythene lined HDPE/SS container.
Sift Magnesium Stearate through SS sieve #80 fitted with vibratory sifter and
collected in double polythene lined HDPE/SS container.
 Granulation: Load the sifted materials into RAPID MIXTURE
GRANULATOR(RMG) with main impeller at slow speed and chopper kept off and
dry mix for 20 minutes. Granulate the materials and the granule mass is formed.
Unload the granules in double polythene lined tared HDPE drums.
 Sifting and Milling: Pass the granules through vibratory sifter fitted with #20
 Blending/Lubrication: All the materials are blended for uniformity and then,
lubricated with collided silicon dioxide and magnesium stearate.
 Compression: The lubricated blend is compressed into tablets.
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FOR F3-F6: DRY GRANULATION:
 Sifting: Acarbose, Corn Starch and Micro Crystalline Cellulose are sifted through SS
sieve #60 fitted with vibratory sifter and collected in double polythene lined
HDPE/SS container.
Sift Aerosil 200, Corn Starch and magnesium stearate through SS sieve #40 in
vibratory sifter and collect in double polythene lined HDPE/SS container.
Sift Micro Crystalline Cellulose, Corn Starch, Aerosil 200 through SS sieve #60 fitted
with vibratory sifter and collected in double polythene lined HDPE/SS container.
Sift Magnesium Stearate through SS sieve #80 fitted with vibratory sifter and
collected in double polythene lined HDPE/SS container.
 Granulation: Load the sifted materials into RAPID MIXTURE
GRANULATOR(RMG) with main impeller at slow speed and chopper kept off and
dry mix for 20 minutes. Granulate the materials and the granule mass is formed.
Unload the granules in double polythene lined tared HDPE drums.
 Sifting and Milling: Pass the granules through vibratory sifter fitted with #20
 Blending/Lubrication: All the materials are blended for uniformity and then,
lubricated with collided silicon dioxide and magnesium stearate.
Compression: The lubricated blend is compressed into tablets.
There was a reduction in the tablet compressibility and low granulation efficiency in dry
granulation method. Hence, wet granulation method was tried which has better granulation
efficiency and compressibility than dry granulation.
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FOR F7 & F8: WET GRANULATION:
 Sifting: Acarbose, Corn Starch, and micro crystalline cellulose are weighed
accurately and mixed thoroughly and sifted through #40 mesh fitted with vibratory
sifter and collected in double polythene lined HDPE/SS container.
 Sifting: Aerosil 200 and Corn Starch and magnesium stearate are weighed accurately
sifted through #40 mesh fitted with vibratory sifter and collected in double polythene
lined HDPE/SS container.
 Sifting: Micro Crystalline Cellulose, Corn Starch are sifted through #40 mesh with
vibrator sifter and collected in double polythene lined HDPE/SS container
 Sifting: Magnesium stearate is sifted through #80 mesh fitted with vibratory sifter
and collected in double polythene lined HDPE/SS container.
 Granulation: Load the sifted material in to RAPID MIXTURE GRANULATOR
(RMG) with impeller at slow speed and chopper kept off and dry mix for 20 minutes.
Add purified water to the contents with impeller at slow speed. Granulate the material
and granular mass is formed. Unload the granules in double polythene lined tared
HDPE drum
 Drying: Load the granular mass to the TRAY DRIER. Air dry the granular mass in
TRAY DRIER for 30 minutes, switch on the heat button and set the temperature to
60ºC and continue at 60ºC, until LOSS ON DRYING(LOD) attains between 2 – 2.5%
w/w.
 Sifting and Milling: Pass the dried granules through vibratory sifter fitted with mesh
#20 and collect the sifted granules in double polythene lined HDPE/SS containers.
Pass  the oversized granules through multimill with 2.0mm screen with knives
forward configuration at medium speed and collect the milled granules in double
polythene lined HDPE/SS Containers.
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 Blending and Lubrication: Load the dried granules into DOUBLE CONE
BLENDER and blend for 15 min. And lubricated for 5 minutes. Unload the blended
mass in double polythene tared HDPE drum.
 Compression: Then the blend is compressed into tablets using CADMACH
compression machine.
PRE-COMPRESSION PARAMETERS:48,49
Angle of repose :
Angle of repose is defined as the maximum angle possible between the surface of pile of
powder and the horizontal plane. The granule mass should allowed to flow out of the funnel
orifice on a plane paper kept on the horizontal surface. This forms a pile of granules on the
paper. The results are show in Table no.8
Tan θ  = h/r
θ = tan-1 (h/r)
Where, h= height of the pile   r= radius of the pile
Bulk density:
A given quantity of the powder is transferred to the measuring cylinder and it is tapped
mechanically either manually or mechanical device till a constant volume is obtained. This
volume is bulk volume (v) and it includes the true volume of the powder and void space
among the powder particles. It is the ratio between a given mass of powder and its bulk
volume. The results are show in Table no.8.
It is the ratio between a given mass of powder and its bulk volume.
Weight of the powder
Bulk density = ------------------------------------
Total weight of powder
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Tapped density :
Tapped density is defined as the ratio between weight of the sample powder taken and the
tapped volume. The results obtained for tapped density are tabulated in Table 8.
Tapped density (Pt) = M/Vt
Where M  =  weight of sample powder taken
Vt = tapped volume
Compressibility index /Carr's index :
Based on the apparent bulk density and the tapped density, the percentage compressibility
index of the powder was determined by using the following formula. The results are shown in
Table no.8.
Tapped density-Bulk density
Compressibility index = --------------------------------------- X 100
Tapped density
Hausner ratio:
By calculating tapped density and bulk density, the Hausner’s  ratio can be calculated. The
results are shown in table no.8.
Hausner ratio = Pt / Po
Where, Pt = tapped density
Po = bulk density
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Table No:5 Flow Properties and Corresponding Angle of Repose, Compressibility Index
and Hausner’s Ratio:
Flow Properties Angle of Repose (θ) Compressibility Index
(%)
Hausner’s Ratio
Excellent 25-30 <10 1.00-1.11
Good 31-35 11-15 1.12-1.18
Fair 36-40 16-20 1.19.1.25
Passable 41-45 21-25 1.26-1.34
Poor 46-55 26-31 1.35-1.45
Very Poor 56-65 32-37 1.46-1.59
Very Very Poor >66 >38 >1.6
POST COMPRESSION PARAMETERS:
Thickness50:
The thickness of the tablets was determined by using micrometer screw gauge and the results
were expressed in millimeter.  ± 5% may be allowed depending on the size of the tablet.
Weight variation test51 :
Ten tablets were selected at random, individually weighed in a single pan electronic balance
and the average weight was calculated. The uniformity of weight was determined according
to LP specification. As per I.P not more than two of individual weight would deviate from
average weight by not more than 5% and none deviate by more than twice that percentage.
Table No:6 Limits of weight variation
S.No. Average weight of tablet Percentage
1. 80 mg or less ± 10%
2. More than 80mg and less than 250mg ± 7.5%
3. 250 mg or more ± 5%
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Hardness test52:
Tablets crushing load, which is the force required to break a tablet by compression in radial
direction was determined by using Monsanto hardness tester. Ten tablets from the batch were
used for hardness studies and results are expressed in Kg/cm 2.
Friability test53:
It was performed in Roche Friabilator apparatus where the tablets were subjected to the
combined effect of abrasion and shock by utilizing a plastic chamber that revolves at 25 rpm
dropping the tablets at a distance of six inches with each revolution. Pre weighed samples of
20 tablets were placed in the Friabilator, which is then operated for 100 revolutions. The
tablets are then dusted and reweighed. Conventional compressed tablets that loose less than
0.5 to 1% of their weight are generally considered acceptable.
Weight loss
%Friability = ---------------------------------------------------------- X 100
Weight of tablets before operation
Disintegration54 :
Disintegration time is the time required for a tablet to break up into granules of specified
size(or smaller size),under carefully specified conditions. The is carried out by  using USP
device which consists of basket-racket assembly, a 1000-ml low beaker,138 to 160 mm in
height and having an inside diameter of 97-115 mm for the immersion of fluid between 35º
and 39 º and a device for raising and lowering the basket for immersion fluid at a constant
frequency rate between 29-32 cycles per minute through a distance not less than 53mm and
not more than 57 mm. The volume of the fluid in the vessel is such that the highest point of
the upward stroke the mesh remains at least 15 mm below the surface of the fluid and
descends to not less than 25mm from the bottom of the vessel on the downward stroke. The
tablet is placed in each of the six tubes of the basket and a disk is added. Operate the
apparatus using the water as immersion fluid maintained at 37±2 º.
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In vitro dissolution studies55:
Procedure :
Tablet dissolution was assessed using standard USP dissolution apparatus type II. The
dissolution media used was 900ml of distilled water. The temperature was maintained at   37
± 0.5°C. At predetermined time intervals, an aliquot of 5 ml sample was withdrawn, and
made up to 10 ml with distilled water. Then these sample were measured in HPLC at 210 nm.
A High Performance Liquid Chromatography system equipped with dual ƛ absorbent detector
and data handling system is used.
Dissolution Parameters :
Apparatus : USP II, Basket
Medium : distilled water
Medium volume : 900ml.
Medium Temp. : 37±0.5oC
Paddle speed : 50 rpm
Sampling Time : 60 min.
Sampling Volume : 5ml.
Absorbance at : 210nm.
Chromatographic conditions:
Column : Phenomenex,5μ (250mm x 4.mm)
Pump Mode : Isocratic
Flow Rate : 1.5 ml/min
Detection : UV, 210 nm
Injection Volume : 20 μL
Run Time : 20 min.
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PROCESS FLOW DIAGRAM OF ACARBOSE-50 mg ALONG WITH CONTROL
VARIABLES:
Figure 2 Process flow diagram.
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PROCESS STEPS, CONTROL VARIABLES AND MEASURING RESPONSES:
Table No:7  process steps, control variable and measuring responses
PROCESS CONTROL VARIABLES MEASURING RESPONSES
SIFTING  VISUAL
INSPECTION
 SIEVE INTEGRITY
DRY MIXING &
GRANULATION
 OCCUPANCY
 GRANULATOR
RPM
 MIXING TIME
 CONTENT
UNIFORMITY
DRYING  DRYING
TEMPERATURE
 DRYING TIME
 DRYING TIME
 LOD
BLENDING /
LUBRICATION
 OCCUPANCY
 BLENDER TIME
 BLENDER RPM
 CONTENT
UNIFORMITY
 BULK DENSITY
 PARTICLE SIZE
DISTRIBUTION
COMPRESSION  MACHINE RPM
 HOPPER LEVEL
 DESCRIPTION
 UNIFORMITY OF
WEIGHT
 DISINTEGRATION
TIME
 HARDNESS
 THICKNESS
 DIAMETER
 FRIABILITY
 % ASSAY
COATING  SPRAY RATE
 COATING PAN
RPM
 BED
TEMPERATURE
 DESCRIPTION
 DISSOLUTION TEST
 WEIGHT GAIN
STRIP PACKING  SEALING
TEMPERATURE
 MACHINE SPEED
 DESCRIPTION
 LEAK TEST
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PROCESS VALIDATION OF ACARBOSE – 50 mg TABLETS:
DISPENSING OF RAW MATERIALS: The raw material that is received from the vendor is
get approved by the quality assurance person, to check whether the product is meets its
specifications in terms of its quality. These raw materials should be tested physically,
chemically and biologically.
SIFTING:
EQUIPMENT USED: Vibratory Sifter- 2.
SIEVE SIZE: # 40, # 80.
WORKING PROCEDURE:
 Acarbose, Starch, Microcrystalline Cellulose PH 101 (Comprecel M101) are weighed
and is sifted in #40 fitted in vibratory sifter and  collected in the pre-labelled double
polythene SS /HDPE containers and is labelled.
 Colloidal sillicon dioxide (Aerosil 200) and Corn starch are weighed and is sifted in
#40 fitted in vibratory sifter and collected in pre-labelled double polythene SS/HDPE
containers and is labelled.
 Corn starch (LOD compensation) is weighed and is sifted in #40 fitted in vibratory
sifter and is collected in pre-labelled double polythene SS/HDPE containers and is
labelled.
 Magnesium Stearate is weighed and is sifted in # 80 fitted to vibratory sifter and
collected in the pre-labelled double polythene SS/HDPE containers and is labelled.
 Visual inspection is done after sifting of each ingredient.
DRY MIXING AND GRANULATION:
EQUIPMENT USED: Rapid Mixer Granulator.
SIZE/CAPACITY: 150 Lts.
MIXING TIME: 30minutes.
WORKING PROCEDURE:
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 Ingredients after sifting is loaded into the Rapid Mixer Granulator and is dry mixed
for 30 minutes.
 Sampling is done at 6 different places and is sent for Assaying at 10, 20 and 30
minutes from dry mixing of ingredients.
 Isopropyl alchohol is added during mixing of the ingredients till desired granular mass
is obtained.
DRYING:
EQUIPMENT USED: Tray Drier.
DRYING TEMPERATURE: 60ºC
WORKING PROCEDURE:
 The granular mass is loaded in the tray drier.
 Dry the granules till LOD attains between 2-3.5% w/w.
 Sampling is done at 3 different time intervals each of 3 gms.
SIFTING:
EQUIPMENT USED: Vibratory sifter -2
SIEVE SIZE: #20
MILLING:
EQUIPMENT USED: Multimil
SCREEN SIZE: 1.5mm
WORKING PROCEDURE:
 The dried granular mass is passed through the vibratory sifter with sieve size #20 and
collect the sifted granules in the pre-labelled double polythene SS/HDPE container .
 The oversized granules are passed through the multimill with screen size 1.5 mm with
the knives forward configuration at medium speed and the milled granules are
collected in the pre-labelled double polythene SS/ HDPE container and note down the
weight.
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BLENDING AND LUBRICATION:
EQUIPMENT USED: Cage blender.
LOAD SIZE: 33 KGS
BLENDER RPM: 25RPM.
BLENDING TIME: 15 minutes.
WORKING PROCEDURE:
 Load the dried granules into the cage blender and blend it for 15 minutes.
 Lubricate the above for 5 minutes.
 Sampling is done at 6 different places after the completion of the lubrication and the
samples are analyzed for content uniformity, bulk density, particle size distribution.
TABLET COMPRESSION:
EQUIPMENT USED: 20 station compression machine.
TURRENT RPM: 25-33 RPM.
PUNCH SPECIFICATIONS:
SIZE: 7.9 mm
SHAPE: circular, shallow, concave.
DIES SPECIFICATION: Suitable for above.
WORKING PROCEDURE:
 Run the tablet compression machine at minimum speed (25 RPM) and sampling is
done when the powder level in the hopper is maximum and minimum and is sent for
the QC analysis.
[QUALITY TESTS: Description, Uniformity of Weight, Thickness, Diameter,
Hardness, Friability, Disintegration Time.]
85
 Run the tablet compression machine at maximum speed (33RPM) and samplings is
done, when the powder level in the hopper is maximum and minimum and samples
are analyzed.
[QUALITY TESTS: Description, Thickness, Diameter, Hardness, Friability,
Disintegration Time.]
 Sampling is done at various settings and speeds from the hopper at the compression
stage.
SETTINGS/SPEEDS:
 Minimum speed, maximum hopper level.
 Minimum speed, minimum hopper level.
 Maximum speed, maximum hopper level.
 Minimum speed, minimum hopper level.
SAMPLING QUANTITY: 50 Tablets at each speed and each powder level.
COATING:
EQUIPMENT USED: Manual coating machine.
COATING PARAMETERS:
Atomising air pressure:  2.5-3.0 kg/cm².
Temperature of inlet air:  60-65 ºC
Distance between spray guns and tablet bed: 10 Inches.
Bed temperature: 40-45 ºC.
Coating pan RPM: 8.
WORKING PROCEDURE:
 Load the compressed tablets in the coating machine and start coating .
 Check the pan RPM while coating starts.
 Check the weight gain for every 15 minutes.
 Sampling is done after coating and the samples are analyzed (approximately 250
tablets)
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[QUALITY TESTS: Description, Weight gain, Thickness, Diameter, Dissolution and
Assay.]
PRIMARY PACKING:
EQUIPMENT USED: Strip Packing Machine.
SEALING HEATER TEMPERATURE: 120ºC-140º C.
WORKING PROCEDURE:
 Set the temperature of strip packing machine at 120º C and run the machine at high
speed (60 cuts / minute) and pack the tablets and leak test is performed for the
samples.
 Set the temperature of the strip packing machine and run the machine at low speed
(40 cuts/ minute) and pack the tablets and leak test is performed for the samples.
SAMPLED QUANTITY: 6 strips at each temperature.
SECONDARY PACKING:
 The strips are packed in the carton which is labelled with the product name, batch
number, manufacturer name, manufactured date, expiry date, and these are filled in
cartons and put into the shipper and sealed and tapped.
 The shipper must have the identity label, tare weight, gross weight, net weight, batch
number, manufacturing date and expiry date.
PROCESS VALIDATION DATA IN THE PRODUCTION OF ACARBOSE 50 mg TABLETS:
DRY MIXING/ GRANULATION:
EQUIPMENT NAME: Rapid mixer granulator
SPEED: Low speed: 80 Rpm.
High speed: 155 Rpm.
TIME INTERVAL: 1 Hour.
BATCH SIZE: 2,00,000.
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SAMPLING LOCATION DIAGRAM IN THE RMG
Figure  no: 3 sampling location in R.M.G
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DRYING:
EQUIPMENT NAME: TRAY DRIER.
TEMPERATURE: 60 ºC.
BATCH SIZE: 2,00,000.
BLENDING AND LUBRICATION:
EQUIPMENT NAME: Cage Blender.
BLENDER RPM: 25 rpm
LOAD SIZE: 33 kg.
BATCH SIZE: 2,00,000.
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SAMPLING LOCATION DIAGRAM
Figure no:4 Sampling location on Cage Blender
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COMPRESSION:
EQUIPMENT NAME: 20 station compression machine.
RPM: 25 – 33.
BATCH SIZE: 2,00,000 Tablets
COATING:
EQUIPMENT NAME: Manual Coating Machine.
ATOMISING PRESSURE: 2.5-3.0 Kg/Cm²
TEMPERATURE OF INLET: 60-65 º C
DISTANCE BETWEEN SPRAY GUNS AND TABLET BED: 10 INCHES.
BED TEMPERATURE: 40-45 º C
COATING PAN RPM: 8 RPM.
SUMMARY:
DRY MIXING:
EQUIPMENT NAME: Rapid Mixer Granulator
BATCH SIZE: 2,00,000.
CAPACITY: 150 lts.
MIXING TIME: 30 minutes.
DRYING:
EQUIPMENT NAME : Tray Drier.
BATCH SIZE:2,00,000
DRYING TEMPERATURE: 60 ºC.
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BLENDING / LUBRICATION:
EQUIPMENT NAME: Cage Blender.
BATCH SIZE: 2,00,000.
BLENDING RPM: 25 RPM
LOAD SIZE: 33 kgs.
BLENDING TIME: 20 minutes.
COMPRESSION:
EQUIPMENT NAME: Tablet Compression Machine (20 Stations).
BATCH SIZE: 2,00,000.
OPTIMUM SPEED: 25-33 Rpm
HARDNESS OF TABLET: 5.18 Kg/cm².
THICKNESS OF TABLET: 3.08mm.
TABLET DIAMETER: 7.95 mm
DISINTEGRATION TIME: 4 minutes 31 seconds.
COATING:
COATING SOLUTION: Opadry
EQUIPMENT USED: Manual Coating Machine.
BATCH SIZE: 2,00,000.
OPTIMUM SPEED: 8 Rpm.
ATOMISING AIR PRESSURE: 2.9kg/cm²
INLET AIR TEMPERATURE: 62 ºC.
DISTANCE BETWEEN SPRAY GUNS AND TABLET BED: 10 inches.
BED TEMPERATURE: 42 ºC.
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STRIP PACKING:
EQUIPMENT USED: Strip Packing Machine.
BATCH SIZE: 2,00,000.
SEALING TEMPERATURE: 136 ºC. MACHINE SPEED: 58 strips per minute.
POST-COATING  PAARAMETERS
Weight gain:
20 uncoated core tablets were taken randomly and the average weight is noted. 20 film
coated tablets are taken randomly and the average weight is noted. The film coating tablets
show 3% coating weight gain which is acceptable as per the limit.
Evaluation of Packing:
Leak test56:
The required number of strips are taken and checked for the quality of strips for any damages.
The collected strips are tied with a rubber band. All the strips must be dipped in water
containing blue dye and the lid is closed. The opening of the dessicator is connected to a
vacuum pump. A  vacuum of 300 mm of Hg is applied and the knob of dessicator is closed.
The vacuum is Kept for 30sec. The vacuum is released by opening the knob of the dessicator
and the strips are removed. Water traces are removed by using the lint free duster. The strips
are opened with scissors. The tablets are checked manually for traces of water inside the
strips. Number of tablets, which have become wet, should not be more than 1%. If the
leakage is more than the above percentage the leak test is repeated.
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RESULTS AND DISCUSSION
PRE-FORMULATION STUDY:
FTIR drug-excipients compatibility
As a part of the  pre-formulation studies drug-excipient compatibility was carried out to study
the possible drug interactions between drug and excipients. The spectrum obtained for the
drug excipients mixture was compared to that of the spectrum of drug alone. The spectrum
for the drug alone and spectrum for the drug excipient are show in figure no:5 and figure no:6
PRE-COMPRESSION PARAMETERS:
Table No:8 Pre-compression parameters for formulation
Formula
Angle of
Repose
(θ)
Bulk
Density
Tapped
Density
Compressibility
Index
(%)
Hausner’s
Ratio
F1 47.01 0.53±0.005 0.62±0.02 32.65±1.06 1.36±0.02
F2 44.08 0.52±0.01 0.61±0.014 24.27±1.06 1.34±0.03
F3 35.36 0.526±0.005 0.61±0.014 14.78±0.18 1.16±0.01
F4 32.23 0.52±0 0.60 14.58±0 1.15±0
F5 29.42 0.526±0.01 0.605±0.01 27.51±0.02 1.163±0.02
F6 29.03 0.523±0.005 0.63±0.08 14.89±0 1.163±0.005
F7 26.71 0.54±0.03 0.64±0.05 15.10±0.51 1.17±0.10
F8 24.70 0.56±0.01 0.64±0.08 14.75±0.61 1.16±0.98
Mean±SD,(n=3)
DISSCUSSION:
The blend was analyzed for parameters such as Angle of Repose, Bulk Density, Tapped
Density, Compressibility Index, Hausner’s Ratio. F1 and F2 showed poor flow ability.
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POST COMPRESSION PARAMETERS:
Table No:9 post-compression parameters for formulation.
Formula Weight
Variation
(Avg SD)
Thickness
(mm)
Hardness
(kg/cm2)
Friability
(%)
Disintegration
Time
F1 188 ±0.30 3.07 2.88 1.12 2min 45 sec
F2 186 ±0.45 3.04 2.81 1.17 2min 40 sec
F3 166 ±0.23 3.02 2.56 1.16 2min 50 sec
F4 164 ±0.12 3.08 4.60 1.17 4min 43 sec
F5 168 ±.021 3.10 2.40 1.14 4min 46 sec
F6 167 ±0.18 3.15 4.56 1.10 4min 42 sec
F7 166 ±0.14 3.03 4.76 0.10 6min 36 sec
F8 165 ±0.28 3.01 5 0.09 4min 50 sec
Msd±n=3
Discussion
Post Compression Observations
 The formulation F1 has shown weight variation problem up to ± 20 mg.
 There was no proper flow of powder into the die cavity.
 The formulation F2 still show weight variation problem indicating poor flowability of
the blend.
 There was a problem in the flow property during the compression
so, the ingredients must be granulated to improve flow properties to reduce the weight
variation.
 The tablets F3 obtained were too brittle.
 The tablets show very less hardness because of the too dry granules formed.
 The granulation in F4 is done in the same manner as that of trial 3 and the granules
are compressed.
 The tablets are shown friability greater than 1% which are not acceptable.
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 The granules of F5 were found to contain more number of coarse particles than fines
and are too dry to form a compactable mass forming brittle granules with less
compressibility.
 A mixture of binders has been used in the F6 to improve the compressibility.
 The Granules formed have shown better compressibility and tablets have been
evaluated for post compression parameters.
 The tablets formed have shown friability of more than 1% which is not acceptable as
per the requirements.
 Disintegration time of the F7 was slightly higher because the granules are well
compacted and  moisture  in the granules holding them compactly.
 A non-polar solvent is used in the F8 to reduce Disintegration Time because of the
vaporization of the solvent forming much drier granules.
 The F8 has good flow properties, the tablets have shown no weight variation and
friability problems.
 The formulation 8 has show disintegration time within the range of 4 minutes.
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ASSAY OF ACARBOSE DURING DRY MIXING
Table No:10 Assay of Acarbose during dry mixing
LOCATION ASSAY OF ACARBOSE (%)
(10 MINUTES DRY MIXING)
LIMIT
BATCH
A
BATCH
B
BATCH
C
1 100.4 99.8 101.3 95.0-105.0% of input.
2 101.5 99.1 101.4 95.0-105.0% of input.
3 101.5 99.1 100.9 95.0-105.0% of input.
4 101.6 99.2 100.2 95.0-105.0% of input.
5 101.3 99.8 100.7 95.0-105.0% of input.
6 101.9 99.0 100.5 95.0-105.0% of input.
MINIMUM 100.4 99.0 100.2 ---------
MAXIMUM 102.6 99.8 101.4 ----------
AVERAGE 101.5 99.3 100.8 ----------
%RSD 0.7% 0.4% 0.4% NMT5%
10 mins DRY MIXING
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ASSAY OF ACARBOSE DURING DRY MIXING
Table No:11 Assay of Acarbose during Dry mixing
LOCATION ASSAY OF ACARBOSE (%)
(20 MINUTES DRY MIXING)
LIMIT
BATCH
A
BATCH
B
BATCH
C
1 102.1 99.7 101.4 95.0-105.0% of input.
2 101.6 102.2 101.0 95.0-105.0% of input.
3 101.1 103.4 100.2 95.0-105.0% of input.
4 102.1 101.1 101.0 95.0-105.0% of input.
5 102.0 99.4 100.1 95.0-105.0% of input.
6 102.2 99.8 100.3 95.0-105.0% of input.
MINIMUM 101.1 99.4 100.2 ---------
MAXIMUM 102.2 103.4 101.4 ----------
AVERAGE 101.9 100.8 100.6 ----------
%RSD 0.4% 1.4% 0.5% NMT5%
20 mins dry granulation.
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ASSAY OF ACARBOSE DURING DRY MIXING
Table No:12 Assay of Acarbose during Dry mixing
LOCATION ASSAY OF ACARBOSE (%)
(30 MINUTES DRY MIXING)
LIMIT
BATCH
A
BATCH
B
BATCH
C
1 102.0 98.5 101.4 95.0-105.0% of input.
2 101.8 98.8 101.5 95.0-105.0% of input.
3 101.8 99.5 102.1 95.0-105.0% of input.
4 102.5 98.8 101.9 95.0-105.0% of input.
5 102.2 98.9 101.4 95.0-105.0% of input.
6 101.7 98.7 101.3 95.0-105.0% of input.
MINIMUM 101.7 98.5 101.3 ---------
MAXIMUM 102.5 98.5 102.1 ----------
AVERAGE 102.0 98.9 101.6 ----------
%RSD 0.3% 0.3% 0.3% NMT5%
30 mins  Dry granulation
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DRYING Table NO:13  LOD of Acarbose.
BATCH
NUMBER
LOD AT DIFFERENT TIME INTERVALS ACCEPTANCE
CRITERIA
INTERVAL 1 INTERVAL 2 INTERVAL3
A 5.46 3.96 2.68 2-3.5%w/w
B 5.90 3.50 2.94 2-3.5%w/w
C 4.6 3.8 2.8 2-3.5%w/w
BLENDING AND LUBRICATION Table NO:14  Parcticle size disrtibution
BATCH
NUMBER
PARTICLE SIZE DISTRIBUTION (IN %)
(RETAINED ON)
BULK
DENSITY
#20 #40 #60 #80 #100 PASS
THROUGH
#100
A 0.00 0.34 2.52 11.19 34.57 50.12 0.47
B 0.01 0.43 2.21 12.85 36.48 47.69 0.50
C 0.50 1.12 7.33 22.89 51.88 14.68 0.51
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COMPRESSION DATA BATCH A
Table NO: 15 Compression Of Acarbose Batch A
PARAMETER SETTING/ SPEED ACCEPTANCE
CRITERIA
1 2 3 4
DESCRIPTION * * * * White to off-white
circular, shallow,
concave, uncoated
tablets plain on both
the sides.
UNIFORMITY OF
WEIGHT
169 169 170 169 165mg ± 7.5 %
(153.0-177.0 mg)160 161 162 161
THICKNESS 3.07 3.08 3.08 3.08 2.90-3.30mm
3.04 3.02 3.04 3.02
DIAMETER 7.93 7.93 7.93 7.93 7.8-8.0 mm
7.89 7.89 7.89 7.89
HARDNESS 4.80 4.81 4.81 4.86 NLT 3.0 kg/cm²
4.56 4.56 4.52 4.60
FRIABILITY 0.06% 0.07% 0.06% 0.07% NLT 1.0 %w/w
DISINTEGRATION
TIME
4 minutes
45seconds.
4 minutes
40
seconds.
4 minutes
45
seconds.
4 minutes
40
seconds.
NMT 15 minutes.
ASSAY 101.1 100.2 100.1 100.9 Assay of Acarbose
should be 90.0-
110.0% of label claim.
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COMPRESSION BATCH B Table No:16 Compression Of Acarbose Batch B
PARAMETER
SETTING/ SPEED ACCEPTANCE
CRITERIA
1 2 3 4
DESCRIPTION
* * * * White to off-white
circular, shallow,
concave, uncoated
tablets plain on both
the sides.
UNIFORMITY OF
WEIGHT
168 169 168 168 165mg ± 7.5 %
(153.0-177.0 mg)162 163 162 163
THICKNESS 3.08 3.08 3.08 3.08 2.90-3.30mm
3.04 3.04 3.04 3.04
DIAMETER 7.92 7.92 7.92 7.92 7.8-8.0 mm
7.89 7.88 7.88 7.89
HARDNESS 4.75 4.76 4.75 4.75 NLT 3.0 kg/cm²
4.35 4.35 4.40 4.40
FRIABILITY 0.08% 0.06% 0.06% 0.07% NLT 1.0 %w/w
DISINTEGRATION
TIME
3 minutes
45seconds.
3 minutes
50
seconds.
3minutes
50
seconds.
3minutes
45seconds.
NMT 15 minutes.
ASSAY 100.5 100.3 100.9 100.8 Assay of Acarbose
should be 90.0-
110.0% of label
claim.
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COMPRESSION BATCH C:
Table No:17 Compression Of Acarbose Batch C
PARAMETER SETTING/ SPEED ACCEPTANCE
CRITERIA
1 2 3 4
DESCRIPTION * * * * White to off-white
circular, shallow,
concave, uncoated
tablets plain on both
the sides.
UNIFORMITY OF
WEIGHT
166 166 167 166 165mg ± 7.5 %
(153.0-177.0 mg)160 160 160 160
THICKNESS 3.10 3.10 3.10 3.10 2.90-3.30mm
3.05 3.05 3.05 3.05
DIAMETER 8.00 8.00 7.94 7.94 7.8-8.0 mm
7.82 7.86 7.91 7.89
HARDNESS 6 6 6 6 NLT 3.0 kg/cm²
5 5 5 5
FRIABILITY 0.08% 0.09% 0.09% 0.10% NLT 1.0 %w/w
DISINTEGRATION
TIME
4 minutes
42 seconds.
4 minutes
46
seconds.
5 minutes 4 minutes
46
seconds.
NMT 15 minutes.
ASSAY 99.6 101.1 99.4 99.7 Assay of Acarbose
should be 90.0-
110.0% of label claim.
103
COATING: Table No:18 Coating Of Acarbose Tablets
TIME % WEIGHT BUILD UP
BATCH A BATCH B BATCH C
Average weight of
core tablets: 165.
Average weight of
core tablets: 164.
Average weight of
core tablets:164
15 minutes. 0.23% 0.21% 0.32%
30 minutes. 0.49% 0.35% 0.46%
45 minutes. 0.70% 0.72% 0.51%
60 minutes. 0.91% 0.89% 0.69%
75 minutes. 1.14% 1.19% 0.89%
90 minutes. 1.37% 1.35% 1.22%
105 minutes. 1.60% 1.56% 1.52%
120 minutes. 1.82% 1.85% 1.79%
135 minutes. 1.97% 1.95% 1.83%
150 minutes. 2.12% 2.10% 2.01%
165 minutes. 2.27% 2.25% 2.06%
180 minutes. 2.42% 2.40% 2.29%
195 minutes. 2.57% 2.55% 2.48%
210 minutes. 2.72% 2.70% 2.52%
225 minutes. 2.90% 2.80% 2.74%
240 minutes. 3.03% 2.92% 3.03%
3.05%
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COATING: Table No:19 Coating of Acarbose Tablets
PARAMETER OBSERVATION ACCEPTANCE
CRITERIA.
Batch
A
Batch B Batch
C
Description * * * White to off
white circular,
shallow, concave,
coated tablets,
plain on both
sides.
Weight gain 3.03 3.05. 3.03 2.8-3.2% weight
gain from average
weight of core
tablets.
Thickness 3.16. 3.18 3.17 3.0- 3.4 mm
Diameter 8.02. 7.99 8.01 7.9-8.1 mm
Dissolution 99.5 100.1 94 NLT 80% of
labelled amount
of Acarbose in
the tablets is
dissolved in 30
minutes.
Assay 99.2% 100.6% 99.7% Assay of
Acarbose should
be 90.0-110.0%of
label claim.
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PACKING
Table No:20 Packing of Acarbose
PARAMETER OBSERVATION
SPECIFICATION
BATCH
A
BATCH
B
BATCH
C
Description White, circular,
biconvex, film
coated tablets
plain on both
the sides.
White,
circular,
biconvex, film
coated tablets
plain on both
the sides.
White, circular,
biconvex, film
coated tablets
plain on both the
sides.
White, circular,
biconvex, film
coated tablets plain
on both the sides.
Leak test Ok Ok Ok Not a single strip
should fail.
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ANNEXURES
Figure No 5: FTIR GRAPH OF ACARBOSE (STANDARD)
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Figure No:6  FT IR GRAPH OF ACARBOSE SAMPLE
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Figure No:7 FTIR OF COMPARISON OF SAMPLE  WITH  STANDARD
109
Figure No:8
HPLC CHROMATOGRAM OF F3
STD-1                                                                      STD-2
Figure No:9
HPLC CHROMATOGRAM OF F4
STD-1 STD-2
Figure No: 10
HPLC CHROMATOGRAM OF F 3
SPL-1                                                                                   SPL-2
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Figure No:11
HPLC CHROMATOGRAM OF F 4
SPL-1 SPL-2
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Figure No:12
HPLC CHROMATOGRAM OF F 5
STD-1                                                                                         STD-2
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Figure No:13
HPLC CHROMATOGRAM OF F 4
SPL-1                                                                                       SPL-2
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Figure No:14
HPLC CHROMATOGRAM OF F 6
STD-1                                                                                                   STD-2
Figure No:15
HPLC CHROMATOGRAM OF F 5
SPL-1                                                                                              SPL-2
Figure No:16
HPLC CHROMATOGRAM OF F 6
SPL-1                                                                                     SPL-2
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Figure No:17
HPLC CHROMATOGRAM OF F 7
STD-1                                                                                     STD-2
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Figure No:18
HPLC CHROMATOGRAM OF F 7
SPL-1
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Figure No:19
HPLC CHROMATOGRAM OF F 7
SPL-2
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PROCESS VALIDATION: ASSAY OF ACARBOSE CORE TABLETS
Batch A:
STANDARD GRAPH:
Figure No:20
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SAMPLE:
Figure No:21
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Batch B:
STANDARD GRAPH:
Figure No:22
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SAMPLE:
Figure No:23
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123
Batch C:
STANDARD GRAPH:
Figure No:24
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SAMPLE:
Figure No:25
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